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G protein-coupled receptors play a key role in cellular signaling by transducing extracellular 
signals via G proteins to elicit intracellular responses. Studies have provided evidence supporting 
the role of the GPCR GPR54 and its cognate peptide ligand, kisspeptin (an RFamide peptide), in 
the regulation of reproduction. Kisspeptin and GPR54 play a critical role in the control of the 
hypothalamic-pituitary-gonadal  axis by regulating gonadotropin-releasing hormone secretion. 
Despite the physiological importance of GPR54/kisspeptin signalling, the GRP54 residues 
important for receptor activation and signalling have not been extensively investigated.  Another 
hypothalamic peptide, gonadotropin inhibiting hormone (also known as RFamide-related peptide), 
which interacts with the GPCR GPR147, has been found to inhibit GnRH-induced gonadotropin 
release and is therefore also of importance in control of the HPG axis. As many of the RFamide 
and RFamide-related receptors and ligands can be promiscuous, there is the potential for cross-
talk between the GPR54/kisspeptin and GRP147/RFRP systems (or other RFamides) which may 
be of importance in the regulation of reproduction. GPR54 chimeras and point mutants were 
constructed in order to investigate the residues important for kisspeptin binding and receptor 
activation. The data obtained indicate that the acidic residues within the extracellular loops of 
GPR54 contribute to cell surface receptor expression and play a role in receptor signalling. In 
order to investigate the interactions of kisspeptin/RFRP peptides at GPR147 and GPR54, binding 
and activation of these receptors was studied with a range of ligands and their analogs. In 
addition to RFRP and its analogs, kisspeptin and several kisspeptin analogs were found to act as 
agonists at GRP147. In contrast, of all the ligands tested, only kisspeptin was able to bind to 
GPR54 with high affinity and elicit a response, thus indicating that GPR54 has high specificity for 
kisspeptin in contrast to the more promiscuous GPR147. These data demonstrate the therapeutic 
potential of kisspeptin analogs, for the inhibition of gonadotropin secretion and treatment of sex 
steroid hormone disease. In addition, these data have identified ligand and receptor residues 
important for binding and activation of GRP54/GRP147 which may aid development of new 
analogs targeting these receptors and highlighted the importance of testing these analogs for 
receptor specificity.  
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This review will focus on the RFamides, kisspeptin and gonadotropin inhibiting 
hormone (GnIH), their cognate receptors, GPR54 and GPR147, respectively, and 
the role they play in control of human reproduction and pubertal maturation and 
development. A special emphasis will also be placed on the structure-activity 
relationship (SAR) of these two ligand-receptor systems. 
1.2 Literature Review 
1.2.1 Introduction to G protein-coupled receptors 
The G protein-coupled receptors (GPCRs) are a large and diverse family of 
membrane proteins consisting of seven transmembrane (TM) helices, an 
extracellular N-terminus and an intracellular C-terminus (Kroeze et al., 2003). 
They are located in the plasma membrane and transduce external signals into 
cells through interactions with extracellular ligands and intracellular G proteins to 
initiate signalling cascades that allow cells to respond to changes within their 
environment. With over 800 members in the human genome, GPCRs represent 
the largest family of proteins involved in signal transduction across biological 
membranes. They are evolutionarily highly conserved (Strotmann et al., 2011) 
and are expressed in most eukaryotic organisms. The molecular structure shared 
by all GPCRs consists of the seven TM domain composed of α-helices spanning 
the plasma membrane. The TM helices are connected by three extracellular 
(ECL) and three intracellular (ICL) loops (Salon et al., 2011).  
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GPCRs in vertebrates are classically divided into five families on the basis of their 
sequence and structural similarity: rhodopsin-like (family A), secretin-like (family 
B), glutamate-like (family C), adhesion (Family D) and Frizzled/Taste (Family 
E)(Fredriksson et al., 2003). The rhodopsin family is by far the largest and most 
diverse of these families, and members are characterized by conserved 
sequence motifs that imply shared structural features and activation mechanisms 
(Foord et al., 2005). The rhodopsin-like GPCRs are the largest family and are 
activated by a diverse range of stimuli (ligands) which include hormones, 
neurotransmitters, and light.   
All GPCRs transduce extracellular signals through interaction with intracellular G 
proteins, of which there are four families (Gs, Gi/o, Gq/11 and G12/13) which are 
characterised by their coupling to different intracellular signalling pathways 
(Hurowitz et al., 2000). 
Over thirty years of cellular, biochemical, and biophysical investigations have 
provided a general overview of how the rhodopsin-like GPCRs function. However, 
these studies still lack a detailed description of the molecular events linking ligand 
binding to receptor activation. The first high-resolution structure, that of  
rhodopsin, was not solved until 2000 (Palczewski et al., 2000), and another 7 
years was needed for the determination of the first GPCRs bound to diffusible 
ligands such as hormones or neurotransmitters (Cherezov et al., 2007,  
Rasmussen et al., 2007. Crystallization of TM proteins is a difficult and 
complicated process which has limited the progress of determining high-
resolution structures of GPCRs. Recent  technological advances in engineering, 
producing and purifying membrane proteins, crystal formation, and X-ray 
diffraction has led to an explosion of GPCR structural biology work. Over the past 
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5 years, 47 structures representing 13 distinct GPCRs have been solved, in many 
cases with resolution of 3 Ǻ or better (Audet and Bouvier, 2012). 
The overall folding of the TM domain is highly conserved among all solved GPCR 
structures and was similar to that of rhodopsin, showing only slight differences in 
the relative orientation of the TM helices. More pronounced variances are found 
in the ECL domains, especially in the second ECL (ECL2) that displays receptor-
specific folds (Rosenbaum et al., 2007). The ECLs and N-terminus, with or 
without part of the TM helical region facing the extracellular space, are 
responsible for ligand recognition. This ligand-binding region is often situated 
within a cavity formed by the TM helices (Pin et al., 2003). The ECL2 of many 
receptors form a compact helical shape adjacent to the TM bundle that, in 
conjunction with ECL1 and ECL3, allows soluble ligands to diffuse easily from the 
extracellular compartment toward the binding site inside of the receptor bundle 
(Rosenbaum et al., 2007).  
In contrast to the extracellular region that has evolved to recognize a very large 
number of diverse ligands, the intracellular region of GPCRs need only to identify 
and differentiate between a relatively small number of G proteins (Mirzadegan et 
al., 2003).  
1.2.2 Introduction to RFamide peptides 
RFamides form a class of neuropeptides characterized by an arginine-
phenylalanine-amide motif at their C-terminus. Members of the RFamide family 
are structurally-related peptides synthesised as precursor proteins, each encoded 
by a distinct gene.  As a result, many of these structurally-related peptides are 
present in an individual species. Some of the RFamide precursors are 
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polyproteins, while others produce only a single ligand. Although members of this 
peptide family are grouped together based on an amidated C-terminal dipeptide, 
they differ in the length and sequence of their N-terminal extensions, which are 
important in conferring distinct binding characteristics and unique activities. 
Because of the structural similarities it is important to delineate the structure 
activity relationships (SARs) of ligands in order to circumvent ambiguity in 
assignment of peptide activity, and thus errors in delineating mechanisms 
associated with signalling and in the design of peptide analogs. Members of the 
RFamide family are predicted to share similarity in ligand–receptor interactions as 
a result of the high degree of structural and functional relatedness across species 
(Bass et al., 2013). 
In mammals, five genes encode the RFamide peptide family members and five 
genes encode their cognate GPCRs, as indicated in Figure 1 with peptide 
sequences of the RFamides displayed in Table 1.  
 
Figure 1: The mammalian RFamide family. The prolactin releasing peptide (PrRP) family, the family of 
NPFF (and related peptides NPAF, NPSF, and NPVF), human RFamide related peptides (hRFRPs), 
metastin/kisspeptins, and QRFP family. Specific receptors for each family of peptides have been identified, 
although in a number of instances cross-talk amongst these peptides and their receptors exists as indicated 
by arrows. Adapted from (Jhamandas and Goncharuk, 2013). 
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The RFamides include the prolactin-releasing peptide (PrRP) family (Hinuma et 
al., 1998), the family of neuropeptide FF (NPFF; and related peptides 
neuropeptide AF (NPAF), neuropeptide SF (NPSF; RFRP1), and neuropeptide 
VF (NPVF; RFRP3) (Bonini et al., 2000,  Liu et al., 2001), human RFamide 
related peptides (hRFRPs) (Hinuma et al., 2000,  Fukusumi et al., 2001), 
metastin/kisspeptins (Ohtaki et al., 2001), and pyroglutamylated RFamide peptide 
(QRFP) (26RFa) family (Chartrel et al., 2003,  Fukusumi et al., 2003). 
The RFamide peptides have been associated with the regulation of most of the 
major pituitary hormones such as prolactin, luteinising hormone (LH), follicle 
stimulating hormone (FSH), growth hormone, adrenocorticotrophic hormone 
(ACTH), oxytocin and arginine vasopressin (AVP), although this regulation may 
be exerted indirectly via other hypophysiotrophic regulatory hormones. They are 
able to influence endocrine functions such as maternal physiology, reproduction, 
growth, stress responses, diuresis and blood pressure regulation (Bechtold and 
Luckman, 2007,  Osugi et al., 2006).  
All mammalian RFamide peptides have been found to be ligands of formerly 
orphan GPCRs. In some cases there is considerable overlap in the binding 
affinity between different RFamides and their receptors with some ligands having 
affinity for more than one receptor, since receptor selectivity appears to be 
determined by the few relatively conserved amino acids at the C-terminus 
(Yoshida et al., 2003).  
 
 




Table 1: Comparison of amino acid sequences of endogenous RFamide peptides in human 
(Findeisen et al., 2011) 
Family Peptide Sequence Reference  
NPFF 
NPFF SQAFLFQPQRF-NH2 
(Tsutsui et al., 2000) 
 




(NPSF) MPHSFANLPLRF-NH2 (Ubuka et al., 2009a,  
Hinuma et al., 2000) 
 
RFRP3 





TSGPLGNLAEELNGYSRKKGGFSFRF-NH2 (Bruzzone et al., 2006,  
Chartrel et al., 2003) 
 
26RFa TSGPLGNLAEELNGYSRKKGGFSFRF-NH2  
PrRP 
 
PrRP31 SRTHR-HSMEIRTPDINPAWYASRGIRPVGRF-NH2 (Hinuma et al., 2000,  
Langmead et al., 2000) 
 









(Kotani et al., 2001,  
Ohtaki et al., 2001) 
 
KP14 DLPNYNWNSFGLRF-NH2  
KP13 LPNYNWNSFGLRF-NH2  
KP10 YNWNSFGLRF-NH2  
Pyroglutamic acid is shown as < E. 
   
1.2.3 RFamides and their cognate receptors 
The discovery of ligand-receptor systems for GPR54/kisspeptin and 
GPR147/RFRP3 followed the discovery of NPFF in mammals. NPFF is a member 
of the RFamide peptide family that is found in the central nervous system and in 
the periphery of several mammalian species including humans and was the first 
RFamide peptide to be identified in mammals (Panula et al., 1996). The gene for 
NPFF has been cloned from human, bovine, rat, and mouse and is highly 
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conserved amongst these species (Hinuma et al., 2000). An NPFF precursor 
protein encodes two proteins, NPFF and NPAF.  
NPFF is able to mediate the antinociceptive effects of opioids (Chen et al., 2006,  
Mouledous et al., 2010) and subsequent studies revealed that NPFF may play an 
equally important role in the central processing of visceral autonomic signals 
related to feeding, generation of central cardiovascular responses, stress, and 
neuroendocrine regulation (Panula, 2009,  Jhamandas and Goncharuk, 2013). 
Concentrations of NPFF and the NPFF receptors in the hypothalamus are 
amongst the highest in the brain (Bonini et al., 2000,  Liu et al., 2001). 
In 2000, Hinuma et al, analysed human genomic and cDNA sequences and 
identified a novel mammalian RFamide peptide gene which they named the 
RFamide-related peptide (RFRP) gene (Hinuma et al., 2000). Isolation of human, 
bovine, rat, and mouse RFRP cDNAs, demonstrated that the human and bovine 
RFRP gene encodes a RFRP precursor protein resulting in 2 peptides: RFRP1 
(also known as RFSF), and RFRP3 (also known as NPVF). Whereas the rodent 
gene encodes only these two peptides, in humans and bovines, an additional 
related peptide (RFRP2) is also encoded by the RFRP precursor protein 
however, this peptide is not believed to be expressed in vivo (Yoshida et al., 
2003,  Ukena et al., 2003). The RFRPs share a similar C-terminal sequence with 
NPFF (see Table 1).  
RFRP1 and RFRP3 are  co-expressed in single neurons in the dorsomedial 
hypothalamus (DMH) (Fukusumi et al., 2001) and fibres containing RFRPs are 
distributed widely within the brain, including in the bed nucleus of the stria 
terminalis, septal areas, amygdala and hypothalamus (Fukusumi et al., 2006). 
Chapter 1: Literature Review 
9 
 
The DMH, where RFRP expressing neurons are localised, plays a pivotal role in 
the control of stress responses in neuroendocrine, autonomic and behavioural 
systems (Kaewwongse et al., 2011). RFRP1 acts in the hypothalamus to inhibit 
dopaminergic neuronal activity (Samson et al., 2003) and RFRP3 has emerged 
as important regulator of reproductive function (Yoshida et al., 2003, Murakami et 
al., 2008). Administration of RFRP1 to rats has been shown to facilitate prolactin 
release from the pituitary (Hinuma et al., 2000) and to attenuate morphine-
induced analgesia (Liu et al., 2001).  While RFRP3 has been shown to inhibit the 
GnRH system in mammals (Johnson et al., 2007, Clarke et al., 2008) and to 
increase food intake (Dockray, 2004).  
In 2000, the putative receptors for NPFF/RFRPs were identified as GPR147 (also 
referred to as OT7TO22 or NPFF1 receptor) and GPR74 (also known as 
HLWAR77 or NPFF2 receptor) (Hinuma et al., 2000,  Bonini et al., 2000,  
Elshourbagy et al., 2000). GPR147 has a high affinity for many RFamide-related 
peptides, including the avian peptide LPLRFNH2, NPFF, NPAF, RFRP1, RPRF2 
and RFRP3 peptides (Bonini et al., 2000,  Elshourbagy et al., 2000,  Liu et al., 
2001). GPR74 has also been shown to bind NPFF and NPAF, RFRP1 and 
RFRP3 (Liu et al., 2001,  Fukusumi et al., 2006).  
For the purpose of this review, the terms GPR147 /GPR74 will be used to 
distinguish between the two receptors and RFRP1/RFRP3 to distinguish between 
the two RFRP peptides 
1.2.3.1 Kisspeptin and GPR54 
Kisspeptins are classified as neuropeptides. They are the endogenous ligand of 
the previously orphan GPCR, GPR54.  They are peptide products of the KiSS-1 
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gene, which was first discovered as a metastasis suppressing gene of malignant 
melanoma cells (Lee et al., 1996). Discovered in Hershey, USA, the gene was 
named after Hershey’s chocolate kisses and the inclusion of SS in the name was 
scientifically indicative that the gene is a cancer suppressor sequence. The ligand 
was initially named metastin and is now referred to as kisspeptin to indicate the 
full length, 54 amino acid peptide. The KiSS-1 gene product consists of a 145 
amino acid precursor protein, which is cleaved to produce a C-terminally 
amidated 54 amino-acid peptide, kisspeptin (KP54). This peptide has biological 
activity and is subsequently cleaved to produce the C-terminal cleavage 
fragments KP14, KP13, and KP10 which also possess biological activity. They 
are collectively referred to as kisspeptin/s (Figure 2).  
Cleavage of the three C-terminal amino acids of kisspeptin by the matrix-
metalloproteases 2 and 9 (MMP-2/9) renders the peptide inactive (Oakley et al., 
2009) and in 2001, Ohtaki et al. reported that the C-terminal KP10 was the 
minimal bioactive sequence of kisspeptins (Ohtaki et al., 2001). High expression 
levels of GPR54 and kisspeptin are present in the placenta, with lower levels in 
the brain, particularly the hypothalamus and the pituitary. The preliminary interest 
in the kisspeptin system focused on its anti-metastatic activity and potential in 
cancer therapy. But, this focus changed in 2003, when several individuals with 
hypogonadotropic hypogonadism (HH) were identified as having mutations in the 
KISS1R gene (Seminara et al., 2003,  De Roux et al., 2003). It has since been 
revealed in many species that kisspeptin, acting via GPR54, is responsible for the 
regulation of the reproductive axis and in particular puberty onset (Tena-
Sempere, 2012).  
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In humans, KiSS-1 mRNA distribution showed high expression levels in placenta, 
pancreas, testis, liver, and small intestine (Lee et al., 1996,  Muir et al., 2001,  
Ohtaki et al., 2001). In addition, KiSS-1 mRNA expressing neurons within the 
hypothalamus have been identified by in situ hybridization in the infunidibular 
nucleus  (Rometo et al., 2007), which is the human equivalent of the arcuate 
nucleus in animals. KiSS-1 has also been found to be co-expressed by GnRH 
neurons (Kelly et al., 2013). This will be discussed in greater detail in subsequent 
sections. 
     
Figure 2: Kiss 1 cleavage products. Kiss1 mRNA is transcribed from the Kiss1 gene and translated to form 
a 145-amino-acid propeptide called kisspeptin-145. Shown are cleavage sites on the propeptide that lead to 
the production of the RF-amidated kisspeptin-54. Shorter peptides (such as kisspeptin-10, -13, and -14) 
share a common C-terminus and RF-amidated motif with kisspeptin-54. (Oakley et al., 2009). 
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As mentioned above, kisspeptins are the endogenous ligands for a GPCR named 
GPR54 (also known as hOT7T175, AXOR12 or KISS1R) (Lee et al., 1999b,  Muir 
et al., 2001). For the purpose of this review the name GPR54 will be used.  
GPR54 was first cloned from rat brain tissue as an orphan receptor. The receptor 
with highest amino acid homology to the kisspeptin receptor is the galanin 
receptor (GAL1), with 45% homology, however galanin does not bind GPR54 
(Lee et al., 1999b). Rat and human kisspeptin receptors share 85% sequence 
identity, increasing to 98% in the transmembrane domains, whereas mouse and 
human share 82% homology. In 2001 kisspeptins were shown to be the 
endogenous ligands for GPR54 (Kotani et al., 2001,  Muir et al., 2001,  Ohtaki et 
al., 2001). All kisspeptins can bind to GPR54, with KP10 having  the highest 
potency (Kotani et al., 2001). 
 In humans, GPR54 mRNA has been detected in the placenta, pituitary, 
pancreas, heart, skeletal muscle, kidney, liver, and also in regions of the brain 
(cerebral cortex, putamen, and medulla) and the spinal cord  (Kotani et al., 2001,  
Muir et al., 2001,  Ohtaki et al., 2001,  Clements et al., 2001). 
The major intracellular signalling system stimulated by GPR54 is the Gq/11 signal 
transduction pathway (Figure 3), which activates phospholipase C (PLC) to 
hydrolyse phosphatidylinositol bisphosphate (PIP2) to inositol trisphosphate (IP3) 
and diacylglycerol (DAG), which, in turn, lead to release of intracellular calcium 
from the endoplasmic reticulum, and activation of protein kinase C, respectively 
(Muir et al., 2001,  Becker et al., 2005). Stimulation of GPR54-transfected cells 
with kisspeptin induces intracellular Ca2+ mobilization, indicating that GPR54 is 
coupled to a Gq/11 G protein pathway (Kotani et al., 2001,  Muir et al., 2001,  
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Ohtaki et al., 2001). GPR54 stimulation also induced the formation of IP3 through 
a PLC-dependent mechanism (Kotani et al., 2001,  Stafford et al., 2002). Greater 
insight into the intracellular signalling pathways activated by GPR54 was derived 
from studies performed either in cell lines (HEK-293, CHO, B16-Bl6, COS-7, NIH-
3T3, MDA-MB-35S, NPA) transfected with the receptor (Kotani et al., 2001,  Muir 
et al., 2001,  Ohtaki et al., 2001,  Becker et al., 2005,  Stafford et al., 2002,  
Stathatos et al., 2005) or in immortalized cell lines natively expressing the 
receptor (GT1-7, Human thyroid carcinoma ARO, AsPC-1, PANC-1) (Masui et al., 
2004,  Stathatos et al., 2005,  Babwah et al., 2012). Data from these studies 
indicated that GPR54 activation was associated with MAPK phosphorylation and 
activation of β-arrestin. Stimulation of the MAPK pathway by kisspeptin could be 
via ERK1/2 stimulation, stimulation of focal adhesion kinase, p38 kinase 
phosphorylation and PI3K/Akt activation (Kotani et al., 2001,  Ohtaki et al., 2001,  
Becker et al., 2005,  Castellano et al., 2006,  Stathatos et al., 2005). Knock-down 
of β-arrestin 2 was able to inhibit ERK1/2 pathway activation, which indicates 
coupling of the β-arrestin to the ERK pathway (Pampillo et al., 2009). This was 
further demonstrated in studies using mouse embryonic fibroblast (MEF) cell lines 
derived from mouse strains lacking β-arrestin-1 and β-arrestin-2, and 
heterologously expressing GPR54.  Both β-arrestin-1 and -2 combined with 
Gq/11 knock-out indicated that the Gq and β-arrestins pathways are 
simultaneously activated by KP10 (Szereszewski et al., 2010). In vivo studies 
have shown that kisspeptin response declined after continuous stimulation 
(Messager et al., 2005,  Seminara et al., 2006,  Jayasena et al., 2010). The 
reduced response is not due to intracellular depletion of GnRH (Messager et al., 
2005,  Seminara et al., 2006), but rather receptor desensitization and/or 
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internalization. Desensitization of GPR54 signalling was found to be mediated by 
serine/threonine kinase 2 (GRK2) and β-arrestin in HEK293-T cells (Pampillo et 
al., 2009).  
Kisspeptins act directly on GnRH neurons to induce a continual depolarization 
event and increase the rate of action potential firing (Han et al., 2005,  Quaynor et 
al., 2007). Rapid recycling of GPR54 to the plasma membrane would ensure that 
non-desensitized receptors capable of sustaining a long-lasting response to 
stimulation would present at the cell surface. An intracellular GPR54 pool that 
could be dynamically recycled to the plasma membrane has been reported 
(Babwah et al., 2012), although GPR54 at the cell surface may not have the 
potential to signal since long lasting  depolarization in GnRH neurons is 
associated with a lack of response to further kisspeptin stimulation (Dumalska et 
al., 2008,  Liu et al., 2008). 
Heterologous expression of kisspeptin has also been shown to result in a 
reduction of cellular invasiveness which was associated with a reduction in 
activity of MMP-9 (Lee et al., 1996). MMPs are a family of enzymes expressed in 
various human tumours and are thought to contribute to tumour invasiveness by 
degrading the extracellular matrix. Kisspeptin mediates its action on MMP 
through inhibition of NFkB translocation to the nucleus (Yan et al., 2001,  Takeda 
et al., 2012). 
 




Figure 3: Summary of the mechanism of GPR54 activation.  Kisspeptin binding to GPR54 activates the 
G-protein Gq/11 and phospholipase C to cleave phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 
triphosphates (IP3) and diacylglycerol (DAG). IP3 causes intracellular Ca2+ release from the endoplasmic 
reticulum, which activates protein kinase C and a kinase phosphorylation cascade (RAF, MEK1/2, and 
ERK1/2). GnRH depolarization is caused by activation of a nonselective cation channel (TRPC) and 
inhibition of an inwardly rectifying potassium channel (Kir) by DAG (D'anglemont De Tassigny and Colledge, 
2010). 
 
1.2.3.2 RFRP3 and GPR147 
Tsutsui et al (2000) identified an RFamide related peptide that inhibited 
gonadotropin release in quail brains and termed it GnIH (Tsutsui et al., 2000). 
Another group identified, using bioinformatics, a mammalian RFamide precursor 
protein in humans that was predicted to give rise to two mature RFamide 
peptides called RFRP1 (also known as NPSF) and RFRP3 (also known as NPVF 
or GnIH) (Hinuma et al., 2000)). Ubuka et al (2009) have since confirmed human 
RFRP1 and RFRP3 as GnIH homologs (Ubuka et al., 2009b).  GPR147 
preferentially binds RFRP1 and RFRP3, whereas GPR74 preferentially binds 
neuropeptides FF and AF (Bonini et al., 2000).  
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The primary sequence of human GPR147 was compared with other known 
GPCRs and indicated that GPR147 shares approximately 30% homology with 
human neuropeptide Y receptor subtype 1, 2 and 4;  34% with human 
cholecystokinin  (CCK) A receptor and 32% with human prolactin-releasing 
hormone receptor (Bonini et al., 2000).  
The GPR147 receptor activates the Gi/o signal transduction pathway which results 
in a decrease in intracellular cAMP levels (Hinuma et al., 2000,  Bonini et al., 
2000) and both RFRP1 and RFRP3 have been shown to inhibit production of 
forskolin (FSK)-induced cAMP accumulation in Chinese hamster ovary  (CHO) 
cells, expressing the human GPR147 receptor (Hinuma et al., 2000).  
Son et al. (2012) investigated the cell signalling pathway of the murine equivalent 
(mRFRP) and its possible interaction with GnRH signalling using a mouse 
gonadotrope cell line, LβT2 in which GPR147 expression had been confirmed by 
RT-PCR (Figure 4) (Son et al., 2012). mRFRP inhibited GnRH-induced cAMP 
accumulation, indicating that mRFRP activated GPR147 functions to inhibit 
adenylyl cyclase (AC). mRFRP was also shown to inhibit GnRH-stimulated ERK 
phosphorylation and transcription of gonadotropin subunits. mRFRP however did 
not affect basal mRNA levels of gonadotropin subunits in the absence of GnRH 
stimulation. Inhibitors of the AC/cAMP/protein kinase A (PKA) pathway, were 
shown to inhibit GnRH-stimulated gonadotropin expression. However, an inhibitor 
of protein kinase C (PKC), did not inhibit GnRH-stimulated gonadotropin 
expression. Together these results indicate that mRFRP functions to inhibit 
GnRH-induced gonadotropin subunit gene transcriptions by inhibiting 
AC/cAMP/PKA-dependent ERK activation in gonadotrope cells (Son et al., 2012). 





Figure 4: Model of the inhibitory mechanism of GnIH on GnRH-induced gonadotropin subunit, LHβ, 
FSHβ, and common α gene transcriptions. The inhibitors of adenylyl cyclase (AC)/cAMP/protein kinase A 
(PKA) pathway, MDL (inhibitor of AC) and H89 (inhibitor of PKA), effectively inhibited GnRH-stimulated 
gonadotropin expressions. On the contrary, the inhibitor of protein kinase C (PKC), GF, did not inhibit GnRH-
stimulated gonadotropin expressions. Accordingly, mouse GnIH may inhibit GnRH-induced gonadotropin 
subunit gene transcriptions by inhibiting AC/cAMP/PKA-dependent ERK activation in LβT2 cells (Son et al., 
2012). 
 
1.2.4 Neuroendocrinology of puberty and reproduction 
Reproductive function is a finely regulated process that ensures continuation of 
the species. A variety of central and peripheral signals interact to control the 
coordinated action of the hypothalamus, pituitary, and gonads, which form the 
gonadotropic (HPG) axis. The hypothalamic decapeptide gonadotropin-releasing 
hormone (GnRH) is a central mediator that carries these regulatory signals down 
to the pituitary level to execute the specific pattern of gonadotropin release (Fink, 
2000). 
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1.2.4.1 Neuroendocrine control of reproduction 
A variety of central and peripheral signals interact to control the coordinated 
action of the HPG axis (Fink, 2000). The function of this neurohormonal system 
depends on the interaction of three major groups of signals arising from: 
 Hypothalamus - where a select group of scattered neurons synthesize 
and release GnRH 
 Anterior pituitary - where gonadotropes secrete the gonadotropins, LH 
and FSH 
 Gonads - generating gametes and are responsible for the synthesis and 
release of sex steroid and peptide hormones (Fink, 2000,  Schwartz, 
2000a). 
These major components of the HPG axis interact via feed-forward loops where 
GnRH stimulates the secretion of gonadotropins which promote gonadal 
maturation and function (Figure 5). Other feedback regulatory loops function 
within this axis, to facilitate the homeostatic regulation of the system in different 
physiological conditions. The GnRH neurons are an important element of this 
system, and GnRH operates as the final output signal for the hypothalamic 
regulation of the downstream elements of the HPG axis. Pulsatile secretion of 
GnRH is critical for achieving and maintaining reproductive function (Belchetz et 
al., 1978,  Santoro et al., 1986). The synchronized release of GnRH bursts is the 
result of the integral function of the GnRH pulse generator that encompasses 
GnRH neurons as well as other afferents and enables the pulsatile secretion of 
GnRH (Knobil, 1988). GnRH secretory patterns are not controlled solely by the 
intrinsic activity of GnRH neurons, but also through the contribution of additional 
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hypothalamic afferents (Maeda et al., 2010). The reproductive axis goes through 
maturational and functional changes during fetal and postnatal development. This 
includes sexual differentiation of the brain and achieving reproductive capability 
at puberty. These processes display sexual dimorphism with detectable 
differences between males and females with regards to the development of 
reproductive brain circuits, the timing of puberty, and the function of the HPG axis 
in adulthood (Fink, 2000,  Herbison, 2006,  Schwartz, 2000a). Examples of these 
differences are the female-specific functional changes of the gonadotropic axis 
during the ovarian cycle, pregnancy, and lactation (Roa et al., 2006,  Schwartz, 
2000b,  Smith and Grove, 2002). Reproductive capability is inherently linked to 
other important functions, such as general health, immune/inflammatory state, 
and energy homeostasis (Fernandez-Fernandez et al., 2006,  Tena-Sempere, 
2007,  Tomaszewska-Zaremba and Herman, 2009), and is sensitive to an 
assortment of environmental triggers, such as photoperiods and stress conditions 
(Kinsey-Jones et al., 2009,  Li et al., 2010,  Simonneaux et al., 2009). Thus 
reaching and maintenance of reproductive capability is dependent on appropriate 
interactions of a diversity of endogenous and exogenous regulators, including 
circulating hormones, neuropeptides, neurotransmitters, and metabolic products, 
which are partially able to impact on the GnRH pulse generator to mediate their 
regulatory actions (Fink, 2000,  Herbison, 2006,  Schwartz, 2000b). GnRH 
neurons are controlled by a variety of interacting trans-synaptic and glial inputs 
(Herbison, 2006,  Ojeda et al., 2006,  Ojeda et al., 2009). Glial cells are now 
recognized as a source of critical facilitatory signals for puberty onset and adult 
reproduction, such as glial-derived growth factors and glutamate, with stimulatory 
effects of GnRH release (Ojeda et al., 2006,  Ojeda et al., 2009). Neuronal 
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afferents are crucial components in synchronizing triggering of pulsatile GnRH 
secretion (Herbison, 2006,  Ojeda et al., 2008). Recently, neuronal transmitters 
have been partially elucidated, with the recognition of the roles of glutamate and 
norepinephrine as major excitatory signals, and GABA and endogenous opioids 
as key inhibitory factors (Ojeda et al., 2009), although GABA can also directly 
excite GnRH neurons under specific conditions (Herbison and Moenter, 2011), 
which illustrates the complex nature of the system.  
The generation of GnRH pulses is therefore not controlled by the isolated action 
of single molecules but rather by the dynamic balance between excitatory and 
inhibitory signals (Christian and Moenter, 2010,  Ojeda et al., 2006).  
 
 




Figure 5: Neurobiology of the hypothalamic-pituitary-gonadal (HPG) axis. Graphic representation of the 
main elements of the neuroendocrine axis controlling reproduction: the HPG axis. Hypothalamic GnRH 
neurons, which receive trans-synaptic and glial inputs, release GnRH to the hypophysial portal blood system. 
GnRH dictates the pulsatile secretion of gonadotropins, LH and FSH that stimulate the maturation and 
regulate the function of the gonads; note that in the scheme, both the ovary and testis are presented. These 
major hormonal elements are connected via feed-forward and feedback regulatory loops. The function of the 
HPG axis is under the regulation of several peripheral signals that include gonadal steroids, responsible for 
feedback control: testicular testosterone (T) conducts inhibitory actions on GnRH/gonadotropin secretion 
(negative feedback), whereas ovarian steroids, mainly estradiol (E2) and progesterone (P), can carry out 
both negative- and positive-feedback actions depending on the stage of the ovarian cycle. Other peripheral 
regulators of the HPG axis are metabolic hormones; among those, the prominent stimulatory/permissive 
roles of leptin, produced by the white adipose tissue (WAT), are depicted. Some of the central transmitters 
involved in the control of the HPG axis are also shown: predominant inhibitory transmitters are depicted in 
red, whereas excitatory factors are labelled in blue. Among the excitatory signals to GnRH neurons, Kiss1 
neurons are highlighted. Please note that to summarize presentation, discrimination between direct and 
indirect afferents to GnRH neurons is not made in the figure. Likewise, for sake of simplicity, some of the 
stimulatory and inhibitory signals to GnRH neurons are depicted in the same neurons; except for the 
Kiss1/NKB/Dyn neurons, this does not denote necessarily coexpression of these molecules in the same 
cells. Glu, glutamate; GABA, γ-aminobutyric acid; EOP, endogenous opioid peptides; NE, norepinephrine; 
NKB, neurokinin-B; Dyn, dynorphin; RFR, RF-related peptides (Pinilla et al., 2012). 
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1.2.4.2 Role of Kisspeptin in puberty and reproduction 
In 2003, two independent reports documented the presence of deletions and 
inactivating mutations of the GPR54 gene in patients suffering familial or sporadic 
forms of idiopathic HH, a rare condition of impuberism, defective gonadotropin 
secretion, and infertility of central origin (De Roux et al., 2003,  Seminara et al., 
2003). The findings were the first to recognise the crucial roles of GPR54 and its 
ligands in the control of key aspects of reproductive function. These important 
findings in humans were strengthened by the report that mice engineered to lack 
functional GPR54 showed a very similar hypogonadotropic hypogonadism to that 
of affected patients (Funes et al., 2003,  Seminara et al., 2003), a condition that 
was later confirmed in Kiss1 null mice (D'anglemont De Tassigny et al., 2007,  
Lapatto et al., 2007), even though Kiss1 KO animals appear to have a less 
severe reproductive impact than GPR54-deficient mice (Colledge, 2009).  
The initial studies on patients with inactivating mutations and deletions of GPR54 
gene lead to many subsequent studies on the reproductive dimension of 
kisspeptins and began the characterization of the major physiological features of 
this system in the control of the HPG axis. Neuroendocrine characterization of 
humans with inactivating mutations/deletions of the GPR54 gene evidenced that, 
despite their striking phenotype in terms of sexual immaturity, failure of gonadal 
function, and hypogonadotropism, the affected individuals retained their capacity 
to respond to exogenous GnRH (Seminara et al., 2003). This feature excluded a 
primary defect at the pituitary level as cause for their HH, in contrast to previously 
reported cases of inactivating mutations of the GnRH receptor (De Roux et al., 
1997). Analyses of GPR54 null mice demonstrated that the hypothalamic content 
of GnRH was preserved (Seminara et al., 2003). This observation ruled out the 
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possibility of a defective migration of GnRH neuron precursors from the olfactory 
placode, as had been proven the case for other monogenic forms of HH, such as 
those associated with mutations in KAL1 or FGF receptor 1 (FGFR1 or KAL2) 
genes (Albuisson et al., 2005,  Dode et al., 2003,  Shahjahan et al., 2010). In 
spite of some phenotypic variability among mouse models, the conserved GnRH 
migration/content in the hypothalamus was later confirmed in KiSS-1 knockout 
mice (D'anglemont De Tassigny et al., 2007). 
The lack of obvious defects in GnRH neuronal migration, GnRH synthesis, or 
pituitary responsiveness to GnRH in individuals with impaired kisspeptin 
signalling implied that the kisspeptin/GPR54 system is a crucial, excitatory 
upstream regulator of GnRH neurons such that absence of kisspeptin signalling 
would result in suppressed GnRH secretion. This hypothesis was put forward 
before key findings such as the identification of kisspeptin neurons at the 
hypothalamus, the potent effects of kisspeptins on GnRH/ gonadotropin 
secretion, and the expression of GPR54 in GnRH neurons. These initial 
discoveries and hypothesis lead to the rapid progress of knowledge of the major 
features of the hypothalamic kisspeptin system as key regulator of the 
gonadotropic axis and have allowed the formation of an outline where kisspeptin 
neurons are upstream of GnRH neurons and act on them directly, with a role in 
switching on GnRH secretion at puberty (Figure 6). 




Figure 6: First hypothesis and current view for the central control of the HPG axis by the Kiss1 
system. A tentative model is presented in the left panel for the original hypothesis on the roles of kisspeptins 
in the central control of the HPG axis, as delineated on the basis of initial findings in humans and mice with 
null mutations of the GPR54 gene suffering hypogonadotropic hypogonadism (HH). Analyses in affected 
individuals revealed that HH was not due to defective pituitary responsiveness to GnRH, neither was it 
caused by lack of migration of GnRH neurons from the olfactory placode at early developmental stages. 
These observations indirectly pointed out that GPR54 signalling was essential for proper GnRH secretion. 
Yet, at that time, the existence of Kiss1 neurons and the expression of GPR54 in GnRH neurons remained 
unknown. In the right panel, a brief view of the current understanding of the kisspeptin neuronal networks 
governing GnRH secretion and, hence, reproductive function is depicted. Of important note, the 
neuroanatomical features of Kiss1 neurons schematically depicted here are taken from rodent data, as 
studies in these species have dominated the field. It is stressed that these characteristics may not fully 
represent the situation in other species, such as primates. Kp, Kisspeptins; KB, neurokinin-B; Dyn, 
dynorphin; KNDy, Kiss1/NKB/Dyn neuron; ARC, arcuate nucleus; AVPV, anteroventral periventricular 
nucleus (Pinilla et al., 2012). 
 
Chronic central administration of kisspeptin in prepubertal female rats advances 
the age of puberty (defined as the age of vaginal opening) (Navarro et al. 2004). 
Recent work by Pineda and colleagues using a newly developed kisspeptin 
antagonist, p234, shows that blocking kisspeptin action delays puberty in female 
rats (Pineda et al. 2010). The role of kisspeptin in puberty in the primate is 
supported by an increase in Kiss1 mRNA in the hypothalamus of pubertal 
monkeys compared to juvenile monkeys of both sexes (Shahab et al. 2005). In 
addition to kisspeptin, other neuropeptides have also been identified as potential 
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regulations of GnRH and/or kisspeptin neurons. Recent work has found that 
mutations in neurokinin B and its receptor (Neurokinin 3 receptor,NK3R) are also 
implicated in cases of isolated HH (Topaloglu et al. 2009). Interestingly, NKB 
expression is colocalized with kisspeptin in ARC kisspeptin neurons (Goodman et 
al. 2007). The role of body mass and leptin, the cytokine produced by white 
adipose tissue, in puberty and the control of the reproductive axis has been 
investigated for many years. It is known that low body mass is responsible for 
delayed puberty and oligo‐ or amenorrhoea. Furthermore, leptin and leptin 
receptor mutations have been found in human patients with disorders of puberty. 
A high proportion of kisspeptin neurons express leptin receptors (Smith et al. 
2006), suggesting that leptin acts through kisspeptin neurons to influence the 
reproductive axis. Smith and colleagues also demonstrated that Kiss1 mRNA is 
reduced in the arcuate nucleus in the hypothalamus of mice deficient in leptin 
(ob/ob mice). A study by Navarro et al (Navarro et al. 2004) found that 
administration of kisspeptin could advance the age of puberty despite food 
deprivation, immunizing the rat against leptin, or in obese Zucher rats (a model of 
leptin resistance). These studies may indicate one therapeutic use of kisspeptin 
in the future. 
1.2.4.3 Interactions of Kiss1 Neurons with RFRPs 
The discovery that kisspeptins play a major role in the control of the HPG axis, 
has led to the re-examination of the proposed mechanisms and neuronal 
pathways whereby other central and peripheral signals regulate the 
GnRH/gonadotropin system. These studies will hopefully aid in the clarification of 
the hierarchy and interplay of kisspeptins and other relevant input signals 
controlling GnRH neurons.  
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Substantial attention has recently been dedicated to elucidating the interactions 
between kisspeptins and RFRPs as mammalian RFRPs have been shown to 
function as putative gonadotropin-inhibitory signals in several different 
mammalian species (Clarke et al., 2009,  Smith and Clarke, 2010,  Tsutsui et al., 
2010). These studies indicate that RFRPs are an inhibitory signal for the HPG 
axis, probably acting at both central (likely on GnRH neurons) and pituitary levels. 
The structural and functional commonalities between kisspeptins and RFRP, 
since both belong to the superfamily of RFamide peptides and participate in the 
control of the HPG axis, although with opposing actions, made it appealing to 
suggest that it is the dynamic balance and interplay between these two sets of 
factors that drives the function of the reproductive system (Kriegsfeld et al., 
2006). However, the integral role of these peptides in the central control of 
reproduction has not been fully confirmed in mammals, in part because the extent 
and physiological relevance of RFRP effects on the gonadotropic axis appear to 
be less pronounced than those of kisspeptins. Nevertheless, the available 
evidence is compatible with an anatomical and functional interplay between the 
inhibitory and stimulatory pathways in the control of some aspects of reproduction 
in mammals. Morphological and expression data support the presumed interplay 
between kisspeptin and RFRP systems in different species. In sheep, studies 
have documented an inverse correlation between the expression levels of KiSS-1 
and RFRP mRNAs in the ARC and dorsomedial nucleus (DMN), respectively, 
during the breeding season, when the number of appositions to GnRH neurons 
also changes inversely showing increased number for kisspeptin neurons and a 
decreased number for RFRP neurons (Smith et al., 2008). These observations 
suggest that kisspeptins and RFRP reciprocally interact to regulate GnRH 
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neuronal activity. Such interplay may involve not only direct, opposite actions at 
the level of GnRH neurons, but might also include reciprocal regulatory effects in 
terms of expression or biological actions. Rat studies have documented 
prominent expression of GPR147 in the AVPV, which might suggest a modulatory 
role of RFRP on kisspeptin neurons in this area (Quennell et al., 2010). 
Functional electrophysiological analyses have also shown RFRP3 to inhibit the 
excitatory actions of kisspeptins on POMC neurons (Fu and Van Den Pol, 2010). 
Although the differences in the degree of absolute gonadotropin responses to 
kisspeptins and RFRPs have precluded direct analysis of their co-administration 
in vivo, combined injection of KP10 and an antagonist of GPR147 modestly 
increased the responses to KP-10 alone (Pineda et al., 2010c). These data 
strongly suggest the possibility of interactions between kisspeptins and RFRP in 
the control of the HPG axis. The physiological relevance of the kisspeptin-RFRP 
interaction is not without controversy. Several reports have failed to show 
reciprocal changes between KiSS-1 and RFRP expression. During the late 
follicular phase in the monkey or the pubertal period in the rat, both KiSS-1 and 
RFRP are upregulated at the hypothalamus (Quennell et al., 2010,  Smith et al., 
2010).  
While the role of kisspeptins in key reproductive phenomena, such as puberty 
onset or the preovulatory surge of gonadotropins, is well documented, the roles of 
RFRP pathways in those events appear to be much more modest, if any (Clarke 
et al., 2009,  Smith and Clarke, 2010). Big differences exist in the major sites of 
actions of kisspeptins and RFRP, as RFRP seems to function partially via 
inhibition of GnRH actions directly at the gonadotrope level (Clarke et al., 2008,  
Pineda et al., 2010b). Lastly, the role of RFRPs in mammalian reproduction 
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varies across species, with a more prominent role in seasonal breeders (Smith 
and Clarke, 2010). GnIH was first identified and plays a prominent regulatory role 
in birds, where the kisspeptin system has been apparently eliminated during 
evolution (Tsutsui et al., 2010). The coevolution of both systems is thus under 
opposite forces, with a reciprocal equilibrium between the dominant roles of 
kisspeptins or GnIH/ RFRP, depending on the species and its reproductive 
strategy.  
1.2.4.4 Potential interaction between kisspeptin and neurokinin B pathways 
Of the various neuropeptides that possibly interact with kisspeptins in the control 
of the HPG axis, NKB has attracted most of the attention recently. NKB belongs 
to the family of tachykinins, which includes also neurokinin A (NKA), substance P, 
and hemokinin-1, as well as neuropeptides K and Y (Almeida et al., 2004). Three 
tachykinin receptors have been identified to date: NK1R, NK2R, and NK3R. NKB 
preferentially activates NK3R, which is considered the canonical NKB receptor. 
The gene encoding NKB is named TAC3 in humans and Tac2 in rodents, 
whereas NK3R is encoded by the TACR3/Tacr3 gene (Rance et al., 2010). The 
roles of NKB and other tachykinins in the regulation of gonadotropin secretion 
had been previously addressed in various species (Rance et al., 2010,  Kalra et 
al., 1991,  Sandoval-Guzmán and Rance, 2004).  Interest in the participation of 
NKB and NK3R in the control of the HPG axis has recently grown considerably, 
due mainly to two observations. Firstly the initial demonstration in sheep that the 
population of Kiss1 neurons located at the ARC actually coexpress NKB, as well 
as the endogenous opioid peptide, dynorphin (Dyn) (Goodman et al., 2007); and 
secondly that inactivating mutations in TAC3 and TACR3 in humans are 
associated with HH (Topaloglu et al., 2009), a phenotype similar to that 
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previously reported for inactivating GPR54 mutations. These observations 
highlighted the important physiological role of ARC neurons expressing 
kisspeptins and NKB, as well as other neuropeptides, such as Dyn, in the control 
of mammalian reproduction. 
The physiological importance of NKB in the control of the HPG axis was 
highlighted when the association between inactivating mutations in TAC3/TACR3 
and human cases of HH was discovered (Topaloglu et al., 2009). These 
associations renewed interest in previous functional studies that addressed the 
roles of NKB in the control of gonadotropin secretion, and lead to new 
investigations to elucidate the effects of NKB in the regulation of GnRH neurons 
and its potential interplay with kisspeptins and other cotransmitters, such as Dyn. 
The published data on the effects of NKB or the agonist of NK3R, senktide, on LH 
secretion has contradictory observations, with either null, inhibitory, or stimulatory 
actions being reported. Administration of an NK3R agonist, senktide, to 
ovariectomized (OVX) mice or rats, without hormonal replacement or very low 
estrogen substitution, resulted in inhibition of LH secretion (Kinsey-Jones et al., 
2009,  Navarro et al., 2009,  Sandoval-Guzmán and Rance, 2004), an effect that 
seems at odds with the reported state of hypogonadotropism in humans with 
genetic inactivation of the NKB system. Additionally, NKB did not result in 
changes in LH secretion in adult male mice (Corander et al., 2010), although a 
different group reported robust gonadotropin responses following icv 
administration of the NK3R agonist senktide in male mice (Navarro et al., 2011). 
In agreement with the Navarro et al. 2011 study, evidence has been offered for 
the potent stimulatory effects of NKB and/or senktide on LH secretion in the adult 
ewe and juvenile monkey (Billings et al., 2010,  Ramaswamy et al., 2010), with 
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the stimulatory effects in the ewe being detected during the follicular phase of the 
cycle. Robust LH releasing responses to icv injection of senktide in cyclic female 
rats and OVX rats with physiological supplementation of estradiol has also been 
reported (Navarro et al., 2010). Pretreatment with a GnRH antagonist was able to 
abolish the observed senktide effect in monkeys (Ramaswamy et al., 2010). 
Thus, under some physiological conditions, NKB signalling can exert potent 
stimulatory effects on GnRH secretion, thereby activating LH secretion. These 
reports indicate that the stimulatory actions of NKB are less conserved than those 
of kisspeptins and are most likely dependent on numerous physiological 
parameters, such as the sex steroid milieu and early brain differentiation, 
endogenous GnRH secretory activity, and developmental stage. Species 
differences may also contribute as indirectly supported by initial reports showing 
that, in contrast to humans, mice with inactivating mutations of Tacr3 gene 
appeared to have preserved fertility (Siuciak et al., 2007).  
The additional presence of Dyn in neurons expressing kisspeptin and NKB 
(termed KNDy neurons) has encouraged functional analyses of the gonadotropic 
effects of this neuropeptide. Dyn is a member of the family of endogenous opioid 
peptides encoded by the prodynorphin gene that acts via the kappa opioid 
receptor (KOR) (Yen et al., 1985).  Dyn has been reported as an inhibitor of 
gonadotropin secretion (Goodman et al., 2004,  Yen et al., 1985). Dyn has been 
shown to inhibit LH secretion in mice, and pulsatile LH secretion in goats 
(Navarro et al., 2009,  Wakabayashi et al., 2010).  
Studies performed in mice and goats suggest that NKB and Dyn may function as 
positive and negative modifiers of the pulsatile release of kisspeptins by KNDy 
neurons at the hypothalamic arcuate nucleus (ARC)  (Navarro et al., 2009,  
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Wakabayashi et al., 2010). As suggested by this model, NKB and Dyn would act 
autosynaptically on ARC KNDy neurons, which in turn would project to and 
activate GnRH nerve terminals at the median eminence, using kisspeptin as 
output neuropeptide effector. Additional support to this autoregulatory mode of 
action stems from the observation that senktide, as agonist of NKB, can activate 
KiSS-1-expressing neurons in the ARC of female rats (Navarro et al., 2011,  
Navarro et al., 2010), but was unable to stimulate LH secretion in GPR54 knock-
out mice (García-Galiano et al., 2012). Further observations in the monkey 
suggest that the stimulatory actions of NKB on GnRH secretion take place 
upstream of GPR54 (Ramaswamy et al., 2011). This hypothetical model 
combines a wide diversity of functional and anatomical observations, but further 
confirmation is required to determine its validity in different mammalian species 
and both sexes. Additional investigations are also required to determine if the 
actions of NKB and Dyn are conducted on the same neuron releasing the 
neuropeptides or upon adjacent and/or contralateral KNDy neurons in the ARC, 
as this neuronal population is interconnected (Ramaswamy et al., 2011).  
1.2.4.5 Distribution of Reproductive Neurons 
GnRH neurons originate in the olfactory placode (Schwanzel-Fukuda and Pfaff, 
1989,  Wray et al., 1989). From the placode, the cells migrate and colonize the 
basal forebrain in and around the preoptic area (POA) and the mediobasal 
hypothalamus (MBH) (Wray, 2002). GnRH is secreted into the hypophyseal portal 
system to stimulate gonadotropin release. The anatomical arrangement of the 
hypothalamus, median eminence (ME) and the pituitary gland allows for delicate 
control of the gonadotropes of the pituitary gland. The GnRH neurons project to 
the external secretory zone of the median eminence, where terminals are found 
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in close proximity to the primary capillary bed of the hypophyseal portal system 
(Page and Dovey-Hartman, 1984). GnRH neurons are surrounded by kisspeptin 
fibres (Irwig et al., 2004) and express GPR54 mRNA (Han et al., 2005). 
Kisspeptin neurons are found in two distinct nuclei in the hypothalamus of the 
mammalian brain: the AVPV nucleus and the ARC nucleus (Navarro et al., 2009,  
Mayer et al., 2010). Kisspeptin neurons of the AVPV nucleus increase GnRH 
release, bringing about the onset of puberty (Mayer et al., 2010). In females, 
kisspeptin neurons in the AVPV nucleus control the preovulatory surge of LH 
through activation by high concentrations of estrogens and progesterones 
(D'anglemont De Tassigny and Colledge, 2010). Kisspeptin neurons of the ARC 
nucleus typically modulate the pulsatile release of GnRH in males and females. 
Males do not have many kisspeptin neurons in the AVPV nucleus due to 
masculization of the AVPV area during neonatal development (D'anglemont De 
Tassigny and Colledge, 2010,  Colledge, 2004). 
In humans, the fully processed forms of RFRP homologs (RFRP1 and 3) were 
identified in an extract of hypothalamus. RFRP immunoreactive (RFRP-ir) 
neurons were observed in the dorsomedial hypothalamic area (DMH). RFRP-ir 
axon terminal like structures were observed in close proximity to GnRH neurons 
in the POA implying the regulation of GnRH neurons by RFRP. The receptor, 
GPR147, was found to be expressed in the hypothalamus. RFRP-ir axons also 
projected to the neurosecretory zone of the ME suggesting that RFRP might also 
directly regulate pituitary function. The expression of the human GPR147 mRNA 
in the pituitary supports this theory. RFRP3 homologs may thus regulate 
gonadotropin secretion by inhibiting GnRH neurons as well as directly acting on 
gonadotrope cells in the pituitary (Ubuka et al., 2009a). 
Chapter 1: Literature Review 
33 
 
Distinct populations of TAC3-positive neurons have been recognized in the 
infundibular nucleus, anterior hypothalamic area, septal region, diagonal band of 
Broca, bed nucleus of the stria terminalis, amygdala, and neocortex (Chawla et 
al., 1997,  Pinto et al., 2004). The expression of NKB has been demonstrated in a 
subset of Kisspeptin neurons in numerous species, with Kisspeptin/NKB/Dyn 
colocalization being a specific feature of the ARC/infundibular population of 
kisspeptin neurons, which has been renamed as KNDy to emphasize the 
potential usage of these three neuropeptides (Lehman et al., 2010).  
1.2.5 Other roles of kisspeptin 
Cancer 
The KiSS-1 gene that encodes kisspeptins was first discovered as an anti-
metastasis gene in human melanoma cell lines (Becker et al., 2005,  Takino et 
al., 2003). Dysregulation of tumour necrosis factor-alpha (TNFα) can induce 
cancer development and metastasis, via nuclear factor-kappa (NF-kB) activation. 
TNFα-induced NF-kB activation stimulates cellular mechanisms such as cell 
proliferation, migration, and invasion. Kisspeptin suppresses the migration and 
invasion of breast cancer cells by inhibiting TNFα-induced NF-kB pathway and 
RhoA activation (Lee et al., 1996). KP10 also inhibits MMP-9 expression by 
reducing NF-kB binding to the MMP9 promoter, to cause an inhibition of cell 
migration (Yan et al., 2001). 
Pregnancy- Implantation and placentation 
The kisspeptin system is implicated in other physiological systems, such as 
pregnancy. Similarities exist between the behaviour of invasive placental cells 
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and invasive cancer cells. Angiogenesis, a common feature of both implantation 
and cancer metastasis, is important in establishing the placenta. Kisspeptin acts 
as a vasoconstrictor, a critical phase in angiogenesis, in isolated coronary 
arteries (Mead et al., 2007), suggestive of a role in the vascular system.  
Kisspeptin and GPR54 are located at the fetal-maternal interface. Kisspeptins are 
highly expressed in the syncytiotrophoblast of the human placenta. The outer 
syncytiotrophoblasts lie adjacent to blood vessels allowing kisspeptin to move 
easily into the maternal blood. GPR54 has been identified in the villous and 
invasive extravillous human cytotrophoblasts (Janneau  et al., 2002,  Bilban et al., 
2004). The spatial and temporal expression of kisspeptin and GPR54 in the 
human and rat are similar. Kisspeptin is expressed in the trophoblast giant cells 
of the rodent placenta, which mediate early invasion as they invade the spiral 
arteries and replace the endovasculature. These cells have the same functional 
phenotype as the human extravillous trophoblasts. As in the human, levels of 
KiSS-1 and its receptor gradually decline during placental maturation and are not 
detectable at embryonic  day 18.5 in the rodent (Terao et al., 2004). 
Low levels of plasma kisspeptin can be found in males and non-pregnant females 
(Dhillo et al., 2005). There is a drastic increase in plasma kisspeptin 
concentrations, with a 1000-fold increase in the first trimester of pregnancy, rising 
to a 10,000-fold increase in the third trimester (Horikoshi et al., 2003). The high 
levels of kisspeptin/GPR54 mRNA in trophoblast cells during the first trimester in 
humans corresponds with the time of peak trophoblast invasion when regulation 
of this process is critical. In vitro, KP10 inhibits trophoblast migration and invasion 
(Bilban et al., 2004) suggesting that kisspeptin plays a key role in controlling 
trophoblast invasion and regulating implantation and subsequent development.  
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1.2.6 Natural mutations of GPR54 results in HH and precocious puberty 
Studies of patients with HH greatly increased our understanding of kisspeptin and 
revealed the connection between kisspeptin/GPR54 and puberty/reproduction. 
The frequency of mutations in the GPR54 (or KiSS-1) gene is low even for a rare 
disease such as HH (Cerrato et al., 2006). The first reports of genetic inactivation 
of GPR54 in humans identified a 155 nucleotide deletion, eliminating the splicing 
acceptor site between intron 4 and exon 5, a homozygous L148S point mutation, 
and compound R331X and X399R point mutations of GPR54 in individuals with 
phenotypic HH (Seminara et al., 2003,  De Roux et al., 2003). Other identified 
missense mutations of GPR54 in additional HH patients include; C223R and 
R297L substitutions (compound heterozygote) (Semple et al., 2005), an insertion 
that changes the open-reading frame (Lanfranco et al., 2005), a L102P mutation 
(Tenenbaum-Rakover et al., 2007), and a combined insertion/deletion mutation at 
the 3’ splicing acceptor site of exon 2 (Todman et al., 2005), as well as additional 
rare variants of GPR54 in patients with late-onset HH (Cerrato et al., 2006). A 
homozygous, loss-of-function mutation involving a pF272S substitution in the 
GPR54 peptide sequence has also been described in individuals with severe 
forms of familial HH of early onset (Nimri et al., 2011). A schematic presentation 
of the major known inactivating mutations of GPR54 gene is depicted in Figure 7. 
 
 




Figure 7: Schematic representation of disease-causing mutations of GPR54 gene reported thus far in 
humans. Red dots indicate the inactivating mutations with reference to the reported amino acid substitution. 
The predicted insertion (1001_1002insC) is indicated by a red arrow. The only activating mutation of GPR54 
described so far in humans, as potential cause for precocious puberty is denoted as a blue dot. A 155-bp 
deletion, not displayed in the scheme, was originally reported by de Roux et al. in patients with HH  (Pinilla et 
al., 2012). 
 
Functional analyses of some of these mutations have been performed in 
heterologous cell systems. The effects of the mutations vary significantly, ranging 
from severe impairment of signalling (L148S) to mild or no impact on function 
(ins/del mutation at intron 2). Neuroendocrinological studies of individuals 
revealed that the L102P mutation resulted in a range of clinical manifestations 
ranging from mild to severe gonadotropin deficiency (Tenenbaum-Rakover et al., 
2007). This highlights the importance of the potential interactions between 
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genetic variability at GPR54 and other loci in defining the clinical phenotype 
associated with suppressed kisspeptin signalling. 
Two different missense mutations of the KiSS-1 gene, resulting in P74S and 
H90D substitutions, have been identified in a cohort of children with central 
precocious puberty. Genetic and biochemical analyses of the mutants indicated 
that none of them affected the region encoding the active peptide core of 
kisspeptins; neither did they alter downstream signalling in cellular assays 
(Silveira et al., 2010). The clinical phenotype was more prominent with the P74S 
mutation, identified in a homozygous state in a boy with onset of puberty at 1 year 
of age, and serum incubations from controls and affected individuals suggested a 
greater stability of KP54 caused by the P74S mutation. Further studies in patients 
with precocious puberty of central origin lead to the identification of the first case 
of an activating mutation of GPR54, an autosomal dominant R386P substitution 
which did not result in constitutive activity of the receptor but instead prolonged its 
downstream IP3 response upon stimulation, therefore suggesting decreased 
desensitization (Teles et al., 2008). 
1.2.7 Structure activity relationships (SAR) 
To identify the most important residue/s of a ligand required to activate its 
cognate receptor, it is useful to identify the minimal necessary sequence. SAR is 
an approach designed to find relationships between chemical structure or 
structural-related properties and biological activity of studied compounds. 
Quantitative SARs (QSAR) represent an attempt to correlate structural or 
property descriptors of compounds with activities (Kontogiorgis et al., 
2005).These physicochemical descriptors, which include parameters to account 
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for hydrophobicity, topology, electronic properties, and steric effects, are 
determined empirically or by computational methods. The main principle of SAR 
is that the activity of molecules is reflected in their structure.  Structure-
affinity/activity studies help to characterize the relationship between ligand and 
receptor. Crucial residues of the ligand and receptor required for their interaction 
can be identified and distinguished from non-essential residues. Knowing the 
three-dimensional structure of biologically active ligands is important for the 
elucidation of structure-activity relationships and for the development of potent 
agonists and antagonists (Flohr et al., 2002).  
Within the neuropeptide family, the amidated C-terminal fragment of the ligand is 
essential for interaction with all receptors (Hinuma et al., 2000). One structure-
activity study was used to determine the importance of the C-terminal amino 
acids of NPFF in binding and agonistic activity. Affinities of NPFF analogs were 
tested toward NPFF receptors of the rat spinal cord and the human NPFF2 
receptors transfected in CHO cells. Activity was also evaluated by their ability to 
inhibit AC in NPFF2 receptor transfected CHO cells. The authors found that 
substitutions of phenylalanine8 by a tyrosine, phenylglycine or 
homophenylalanine were deleterious for high affinity. Similarly, the replacement 
of Arginine7 by a lysine or D-Arginine induced a loss in affinity thus highlighting 
the importance of the amidated C-terminal fragment (Mazarguil et al., 2001). 
Having highly selective agonists are as important as specific receptor antagonists 
for functional investigations. The progress made in the development of agonists 
and antagonists for GPR54 and GPR147 is discussed in the following section. 
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1.2.7.1 GPR54/Kisspeptin Agonists 
The discovery of GPR54 and its cognate ligands KP54, 14, 13, and 10, has led to 
structure-activity studies with several peptide and non-peptide ligands. The N-
terminally truncated KP10 is the shortest, highly potent agonist and was the 
template structure for further structure-activity studies (Gutiérrez-Pascual et al., 
2009,  Ohtaki et al., 2001). Niida et al., employed D-amino acid scanning 
experiments of KP10, in which residues were systematically substituted with their 
D-isomer, showed that the five C-terminal residues are stereochemically critical 
for GPR54 activation (Niida et al., 2006). Using similar experiments in which the 
residues of KP10 were systematically substituted with alanine,  the importance of 
residues phenylalanine 6, Arginine9, and phenylalanine 10 were highlighted due to 
a high loss of agonistic activity upon substitution (Niida et al., 2006,  Gutiérrez-
Pascual et al., 2009,  Orsini et al., 2007). This observation was corroborated by 
structural data, which show that these three residues lay on one face of the 
ligands structure and define a pharmacophore site for kisspeptin (Orsini et al., 
2007). Substitution of the C-terminal phenylalanine with tryptophan resulted in 
improved receptor activity (Orsini et al., 2007; Clements et al., 2001).   
 




Figure 8: Sequences and bioactivity of down-sized agonists for the GPR54. Truncated KP10 was used 
as lead structure for developing FTM080 and FTM145. (4-F)Bz: 4-fluorobenzoyl (Oishi et al., 2010). 
 
Following these observations, Niida et al. developed so-called ‘down-sized’ 
analogs of KP10 (FM052a and FM053a) which retained KP10 like agonistic 
activity (Niida et al., 2006). Further optimization of these pentapeptide-based C-
terminal kisspeptin analogs resulted in a potent GPR54 agonist: H-Amb-Nal(2)-
Gly-Leu-Arg-Trp-NH2 (compound 34) (Tomita et al., 2006). Further SAR and 
QSAR studies, performed on the N-terminal acyl groups of the pentapeptide 
agonists revealed that an aromatic acyl group and the inductive electronegative 
as well as small substituents at position 4 of the aromatic ring contributed to the 
agonistic activity and lead to the identification of the GPR54 activating agonist 
FTM080 (Figure 8), which is has a similar potency as KP10 (Tomita et al., 2007). 
An (E)-alkene dipeptide isostere at the glycine-leucine site also was added to 
prevent proteinase degradation under biological conditions and the resulting 
agonist was called FTM145 (Figure 8) (Tomita et al., 2008). Another KP10 analog 
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[D-Y] 1KP10 analog exhibited lower affinity for GPR54 but exhibited similar 
bioactivity in vitro. Peripheral administration of [D-Y] 1KP10 was shown to increase 
plasma LH and testosterone in vivo more potently than KP10 in mice and was 
thus suggested to be more resistant to proteolytic degradation compared to 
KP10. This hypothesis was supported by significantly increased total testosterone 
levels, measured 60 min after injection of 0.15 nmol [D-Y]1KP10  while the same 
dose of KP10 had no significant effect (Curtis et al., 2010). Comparisons of the 
binding activities and potencies of different KP10 analogs are presented in Table 
2. 
 










KP10 YNWNSFGLRFNH2 100.3 ± 7.3a 0.12 0.12 
(Gutiérrez-Pascual et al., 2009,  
Oishi et al., 2010) 
NF1 NRNFLRFNH2 NT NT 800 ± 700 (Clements et al., 2001) 
Trp
7







NRNGLRWNH2 NT NT 200 (Clements et al., 2001) 
[D-Y]
1





2.6a NT 3.3 
(Tomita et al., 2006,  Niida et al., 
2006) 
FM053a Gu-Amb-FGLRWNH2 93.7 ± 1.8a NT 1.4 







0.4a NT 0.82 (Tomita et al., 2006) 
FTM080 (4-F)Bz-FGLRWNH2 NT 0.71 0.45b (Tomita et al., 2007) 
FTM145 
(4-F)Bz-F-G(ψ 
1)LRWNH2 NT 0.12 0.30
b (Tomita et al., 2007) 
Abbreviations: BisPy: bis[(2-pyridinyl)methyl]; Amb: 4-aminomethylbenzoic acid; Gu: guanidine; Nal(2): 3-(2-
naphthyl)alanine; ψ 1: (E)-CH=CH-; (4-F)Bz: 4-fluorobenzoyl; a % activity are based on the relative maximum 
agonistic activity induced by 10 nM of the compounds (%). Maximum agonistic activity signal at 1 μM KP10 
was used as reference (100%). b EC50 values represent the concentration required for 50% of the full 
agonistic activity induced by KP10 (1 μM). NT = not tested. 
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 1.2.8 Therapeutic Potential of RFamides 
The RFamide peptides represent a family with a large therapeutic potential since 
they are involved in several regulatory mechanisms related to energy 
homeostasis, reproduction, pain and behavioural processes like food intake, 
locomotion and stress response. However, due to their structural homology they 
are prone to interact with other GPCRs within this family. This is a major obstacle 
in investigations of the distinct roles for single RFamide peptides. Oishi et al 
(2010) provided an example of this when they showed that KP10 was able to 
interact with  the NPFF receptors (Oishi et al., 2010). Additionally, the NPFF 
receptors (GPR147 and GPR74) themselves both share high affinities to their 
endogenous ligands, NPFF and RFRP3 (Oishi et al., 2010) and the GPR74 has 
been shown to also bind the neuropeptide Y (NPY) receptor 1  antagonist, 
BIBP3226 (Mollereau et al., 2002). The ability of a few RFamide peptides to 
interact with multiple receptors drives the need to ensure that RFamide receptor 
selective agonists as well as antagonists are specific to a single receptor and do 
not cross react with other RFamide receptors.  
Highly selective antagonists have important therapeutic applications and are 
excellent tools for investigating specific physiological effects mediated by 
individual receptors and their ligands.  
1.2.8.1 Kisspeptin Antagonists 
Roseweir et al (2009) created a highly potent peptide antagonist for GPR54  
based on the substitution of leucine at position 8 of KP10 with D-Trp in 
combination with substitution of serine at position 5 with glycine (Roseweir et al., 
2009). This antagonist peptide 234 (p234), reduced pulsatile GnRH secretion in 
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female pubertal monkeys and inhibited the firing of GnRH neurons in the brain of 
the mouse. The inhibitory effect of p234 on LH release in rats and mice and the 
blocking of LH rise in castrated sheep, rats, and mice indicate that kisspeptin 
neurons mediate the negative feedback effect of sex steroids on gonadotropin 
secretion in mammals. Pineda et al.(2010) extended and refined the in vitro and 
in vivo testing of p234 through continuous infusion, and additionally modified the 
p234 with an N-terminal penetrating sequence to increase permeability through 
the blood-brain barrier and creates a path for new strategy for development of 
kisspeptin antagonists (Pineda et al., 2010a).  
 A small molecule GPR54 antagonist with a 2-acylamino-4, 6- diphenylpyridine 
scaffold has also been reported (Kobayashi et al., 2010a,  Kobayashi et al., 
2010b). Kobayashi et al. (2010) identified an analog with a 2-furoyl group to be 
the most suitable of all tested 2-acylamino-4, 6-diphenylpyridines and their SAR 
studies led to compound 9l with an affinity of 3.7 nM in a GPR54 binding assay. 
The compound also displayed antagonistic activity in a cellular functional assay 
(Kobayashi et al., 2010a). An optimized compound, 15a, displayed high affinity to 
human and rat GPR54 and displayed antagonistic activity and high brain 
permeability. Intravenous administration of 15a to castrated male rat curbed the 
plasma LH level, which could lead to the possibility of a small molecule kisspeptin 
antagonist as a novel drug for sex-hormone dependent diseases (Kobayashi et 
al., 2010b).  
1.2.8.2 Antagonists for GPR147 
Several putative antagonists that target NPFF receptors (GPR147/GPR74) have 
been reported. These are compounds derived from endogenous NPFF ligands 
and included N-terminally truncated peptides such as desaminotyrosyl-
Chapter 1: Literature Review 
44 
 
FLFQRFamide, dansyl-PQRamide and PFR (Tic) amide (Malin et al., 1991,  Tan 
et al., 1999,  Prokai et al., 2001). However, most of them act as partial agonists 
with a low affinity which limits their use as pharmacological tools.  
 
 
Figure 9: Structure of GPR147 antagonist, RF9 (Simonin et al., 2006). 
 
Simonin et al (2006) aimed to identify dipeptides that can act as NPFF receptor 
ligands which displayed affinity at NPFF receptors from rat spinal cord. Over 100 
derivatives, produced by substitution of the phenyl ring of N-benzoyl RFamide or 
replacement with other heterocycles (e.g., indole or quinoline), or other 
nonaromatic lipophilic groups (tertiobutyl, cyclohexyl, or adamantane), were 
screened. RF9 and a modified dipeptide was identified as a potent and selective 
benzoyl-RFamide dipeptide antagonist for GPR147, RF2 was identified (Figure 
9). RF9 dose-dependently reversed the inhibitory effect of RFRP3 on LH release 
with an EC50 of 4.7 ± 1.2 μM , thus confirming that this compound displays 
antagonist activity at GPR147 (Simonin et al., 2006). Blockade of GPR147 by 
central administration of RF9 resulted in very robust LH and, to a lesser extent, 
FSH secretory responses in rats and mice. Distinct differences were detected, in 
terms of threshold doses and relative magnitude, between both gonadotropins. In 
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male rats, significant LH responses to RF9 were detected at doses of 1 nmol icv, 
with a maximal 8-fold increase over basal levels at doses of 20 nmol. In contrast, 
elevation of FSH levels was observed only after icv injection of maximal doses of 
RF9 (20 nmol), which accounted for a 65% increase over corresponding basal 
concentrations (Pineda et al., 2010c).  




There is intense ongoing research into kisspeptin and RFRP3 to further 
characterize the role that these two neuropeptides play in regulating puberty and 
reproduction. While this is important, it is equally important to try and discover 
how these ligands interact with their receptors and with other neuropeptide 
receptors especially for the purposes of designing novel agonists and antagonists 
targeting these receptors that may have therapeutic use. In particular, information 
facilitating the design of novel GPR147 ligands that are specific and do not cross 
react with other receptors would be especially useful. Although naturally-
occurring human mutations have been identified in GPR54, there have been no 
classical mutagenesis studies on this receptor. Therefore, this thesis aimed to 
address these interactions in more detail.  Furthermore, as there is much 
controversy surrounding the interplay between GPR54/kisspeptin and 
GPR147/RFRP3 pathways,  the cross-reactivity of kisspeptin/RFRP3 analogs at 
these receptors has therefore been examined.   
The specific objectives of this thesis were to investigate: 
 The role of the N-terminus and extracellular loops of GPR54 in ligand 
binding and receptor activation by employing GalR2-GPR54 chimeras  
 The role of the extracellular loop acidic residues of GPR54 in ligand 
binding and receptor activation 
 The specificity of ligands for GPR147 by testing  the affinity of different 
RFamide and RFamide related peptides  
 SAR studies on RFRP3 analogs at GPR147 
 Effects of kisspeptin analogs on GPR147  
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Dulbecco’s minimum essential medium (DMEM), Optimem-1 and Trypsin powder 
were purchased from Gibco (Invitrogen). Fetal Calf Serum (FCS), Penicillin-
Streptomycin and Med-199 were purchased from Highveld Biological 
(WhiteScience). Fugene HD and XtremeGene HP transfection reagents were 
purchased from Roche. Cell culture dishes and plates were purchased from 
Costar. Cell culture flasks were purchased from Corning. Matrigel Basement 
membrane matrix (Matrigel) was purchased from BD Biosciences. Electroporation 
cuvettes were purchased from Biorad. 
The radiochemicals (Myo-[2-3H (N)] inositol, Iodine-125 and Metastin 45-54, [125I] 
([125I]-KP10) were purchased from Perkin Elmer. Scintillation fluid was from 
Zinsser Analytical. Quaternized aminoethyl (QAE) sephadex G25, 1x8-200 
DOWEX-1 and Forskolin were purchased from Sigma. The Dual luciferase 
reporter assay kit and PureYield™ Plasmid Maxiprep system and Plasmid Maxi 
kit were purchased from Promega or Qiagen, respectively. 
Kanamycin and ampicillin antibiotics were purchased from Sigma. 
The GalR2-GPR54 chimera’s (pEYFP) were a gift from Professor Chris Hague 
(University of Washington, USA). The acidic N-terminal FLAG tagged GPR54 
mutants were prepared in pcDNA3.1(+) by GENEART (California, USA). The 
mouse GPR147 expression construct (in pcDNA3.1) was made by Dr Kevin 
Morgan (MRC, Human Reproduction Science Unit, Edinburgh). The pCRE-Luc 
and Renilla (pRL-TK) reporter plasmids were obtained from Clontech and 
Promega, respectively. 
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CCK was purchased from American Peptide Co. All other peptides used in this 
study were purchased from EZBiolab. 
Monoclonal ANTI-FLAG® (Clone M2) antibody was purchased from Sigma. Anti-
GFP (a mixture of clones 7.1 and 13.1) was purchased from Roche. Polyclonal 
goat anti-mouse HRP-conjugated secondary antibody was purchased from Santa 
Cruz. Goat anti-mouse Alexa 488-conjugated and donkey anti-mouse Alexa 488-
conjugated secondary antibodies were purchased from Invitrogen. Donkey anti-
mouse Cy3-conjugated secondary antibody was purchased from Jackson 
ImmunoResearch Laboratories, Inc. DAPI and Mowiol were purchased in-house 
from the UCT Confocal and Light Microscope Facility. 
 
2.2 Methods 
2.2.1 Preparation of competent bacteria 
E.coli DH1α cells were streaked onto a Luria broth (LB) agar (170 mM NaCl, 1% 
tryptone, 0.5% yeast extract and 1.5% agar) plate and cultured overnight at 37˚C.  
Thereafter, a single colony was picked from the plate and inoculated into 5 ml 
sterile LB medium (170 mM NaCl, 1% tryptone and 0.5% yeast extract) and 
cultured overnight at 37˚C. This starter culture was then added to a 2L flask 
containing 500 ml of LB.  The culture was shaken at 37˚C until it reached an 
OD600 of 0.45 nm after which it was centrifuged at  2000g in a fixed angle rotor 
centrifuge (J21,Beckmann) for 10 min at 4˚C. The supernatant was discarded and 
the pellet re-suspended in 100 ml ice cold 100 mM MgCl2.  After 30 min 
incubation on ice, cells were pelleted at 2000g (J21, Beckmann) for 10 min at 
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4˚C.  Supernatant was discarded and pellet was re-suspended in 10 ml of 100 
mM CaCl2 with 15% glycerol.  Aliquots of 100 μL were prepared in 2 ml tubes and 
snap frozen in liquid nitrogen before storage at -80˚C. 
2.2.2 Bacterial Transformation 
Plasmid DNA (1 ng) was added to 100 µl competent bacteria and incubated on 
ice for 30 minutes.  Bacteria were then heat shocked for 30 seconds at 42°C and 
returned to ice for 2 minutes after which 900 µl LB media was added and 
incubated at 37°C for 60 minutes shaking at 250 rpm. Bacteria were then spread 
onto LB agar plates, containing appropriate selective antibiotic (100 mg/ml 
ampicillin or 50 mg/ ml kanamycin) and incubated overnight at 37°C. 
2.2.3 Preparation of plasmid DNA 
A single colony was inoculated into a starter culture of 10 ml fresh LB medium 
containing selective antibiotic (Ampicillin or Kanamycin at 100 mg/ml or 50 mg/ml, 
respectively) and grown for a period of 10 hours at 37°C with shaking at 250 rpm. 
This starter culture was diluted 1/1000 into 250 ml LB medium and cultured for 16 
hours at 37°C with shaking at 250 rpm. Plasmid DNA was purified by using either 
PureYield™ Plasmid Maxiprep system or Plasmid Maxi kit, according to the 
manufacturer’s instructions. Samples were eluted using TE Buffer (10 mM Tris-
HCL (pH8), 1mM EDTA) or water and DNA concentration was determined using 
a NanoDrop 2000 spectrophotometer (Thermo Scientific). 
2.2.4 Preparation of glycerol stocks of transformed bacteria 
Glycerol stocks of transformed E.coli were prepared by adding 400 µl of 80% 
glycerol to 600 µl of bacterial culture that had been grown overnight at 37°C with 
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shaking at 250 rpm. Vials were inverted to mix the glycerol and stored at -80ºC. 
To recover the bacteria, a sterile inoculating loop was used to scrape the surface 
of the frozen culture, keeping the bacteria on dry ice. The bacteria were used to 
inoculate 250ml LB media and, after incubation for 16 hours at 37°C with shaking 
at 250 rpm, plasmid DNA was extracted as described in 2.2.3. 
2.2.5 Agarose gel electrophoresis 
Plasmid DNA and PCR products were separated by agarose gel electrophoresis 
at 120V using 1% agarose gels prepared in TAE buffer (40 mM Tris, 320 mM 
acetic acid, 1 mM EDTA, 10µg/ml ethidium bromide, pH7.2). Thereafter, gels 
were visualised under ultraviolet light using a transilluminator. Fragment size was 
determined using a 1kb DNA ladder (NEB) that was run as a size marker. 
2.2.6 Maintenance of Cell cultures  
COS-7 and HEK293-T cell lines were maintained in DMEM supplemented with 
10% FCS, 2 mM L-glutamine, 100 IU/ml penicillin and 100 IU/ml streptomycin. 
Cells were passaged twice-weekly employing enzymatic dispersal with trypsin. 
The medium was aspirated from the cells and washed with phosphate buffered 
saline (PBS; 137mM NaCl, 2.7mM KCl, 10mM Na2HPO4 and 2mM KH2PO4, pH 
7.4) before trypsin-EDTA (0.05% trypsin and 0.5 mM EDTA in PBS, pH 7.4) was 
added to each flask. Cells were incubated at 37ºC for 3-5 minutes, until detached. 
Trypsin was neutralized by the addition of growth medium. The cell suspension 
was then centrifuged at 600g for 2 minutes and the pellet re-suspended in an 
appropriate volume of medium. Cells were passaged in a 1:10 dilution or seeded 
in plates as needed for experiments. For experiments, HEK293-T cells were 
seeded in dishes treated with 1:30 dilution of Matrigel to aid cell attachment. 
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Flasks/dishes were then returned to the incubator at 37ºC in a humidified 5% CO2 
atmosphere.  
2.2.7 Transfection techniques 
2.2.7.1 Electroporation of COS-7 cells 
COS-7 cells were plated into 15 cm diameter dishes and, at 80% confluence, 
cells were transfected. Cells were detached from the dishes by addition of 
trypsin-EDTA as described previously. Cell suspensions were pooled and 
collected via centrifugation at 600g for 2 minutes. Media was aspirated and the 
pellet gently re-suspended in 5 ml of Optimem-1 electroporation medium. The 
cells were collected by centrifugation at 600g for 2 minutes. The medium was 
aspirated and the pellet re-suspended in 0.7 ml Optimem-1 electroporation 
medium per dish. Thereafter, 0.7 ml of the cell suspension was added to each 
pre-chilled electroporation cuvette containing 10 µg DNA and mixed with gentle 
pipetting. Each cuvette was placed in the electroporation shocking chamber 
(Biorad Gene Pulsar II Electroporation System) and pulsed at 0.22 kV and 960 
μF with an average time constant of 21ms. Cuvettes were then incubated for 10 
minutes at room temperature after which cells were re-suspended in 25 ml cell 
culture medium per cuvette. Transfected cells were then seeded into 12-well 
plates at a density of 1x105 cells/ 1ml for experiments as needed.   
COS-7 cells were used for all radioactive experiments as they attach well and are 
not easily detached during the washing processes. 
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2.2.7.2 Chemical Transfection of HEK293-T cells 
Fugene HD Transfection Reagent: 
Cells were seeded at a density of 1x105 cells/ml in 24-well plates or 5 x104 
cells/ml in 48-well plates. The transfection medium was prepared as follows for 
each DNA construct:  
2 µg DNA per 100 µl serum free medium (SFM; DMEM without 
supplements) 
 6 µl Fugene HD transfection reagent per 2 µg DNA 
Samples were mixed by vortexing and incubated at room temperature for 30 
minutes. 25 or 50 µl of the mixture was then added in a drop-wise manner to 
each well of 48-well or 24-well plates, respectively, swirling to ensure even 
distribution. The plates were then incubated at 37ºC in a humidified 5% CO2 
atmosphere for 48 hours. Transfection medium volumes were adjusted per 
experiment as required. 
X-XtremeGene HP DNA Transfection Reagent: 
Cells were seeded into 24-well plates at a density of 1x105 cells/ml. The 
transfection medium was prepared as follows: 
 1 µg DNA per 100 µl SFM 
 2 µl X-XtremeGene HP DNA Transfection Reagent per 1 µg DNA 
After mixing gently, the transfection mixture was incubated for 15 minutes at room 
temperature. 50 µl of the mixture was then added drop-wise to each well. Plates 
were swirled and incubated at 37ºC in a humidified 5% CO2 atmosphere for 48 
hours. Transfection medium volumes were adjusted per experiment as required. 
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2.2.8 Inositol-(1, 4, 5)-trisphosphate accumulation assays 
COS-7 cells transfected by electroporation were seeded in 12-well plates as 
indicated in 2.2.7.1 and incubated for 24 hours at 37ºC. Thereafter, the medium 
was aspirated and cells were rinsed with 0.5 ml of IP3 media (Med199 
supplemented with 2% FCS) for 15 minutes.  Cells were then labelled with 0.5 
ml/well of 2uCi/ml myo [2-3H (N)]-inositol in IP3 media and incubated for 20 hours 
at 37ºC.  After which cells were incubated with Buffer-I (140mM NaCl, 4mM KCl, 
20mM HEPES, 8mM glucose, 0.1% bovine serum albumin (BSA), 1mM MgCl2, 
1mM CaCl2 and 10mM LiCl) for 15 minutes at 37˚C.  Peptides were diluted (0-
1µM) in Buffer- I and added to the cells for 90 minutes at 37˚C.  The media was 
then aspirated and 1 ml of 10 mM formic acid added to each well and incubated 
at 4˚C for 30 minutes to permeabilise the cells and release radiolabelled inositol 
phosphates.   
Columns packed with Dowex 1x8-200 ion-exchange resin (Sigma) were washed 
sequentially with 3 ml 3M ammonium formate/0.1 M formic acid and 10 ml 
distilled water. The cell extracts were then added to the columns, followed by 10 
ml distilled water and then 5 ml 0.1 M ammonium formate/0.1 M formic acid.  
Samples were then eluted from the columns in 1 ml 1M ammonium formate/0.1M 
formic acid.  Scintillation vials were prepared with 2.6 ml scintillation fluid and 1 
ml of elute was added to each vial and mixed well.  Sample radioactivity was 
measured in a Tri-carb 2100TR liquid scintillation analyser (Packard). 
2.2.9 Live cell imaging  
Untransfected and WT-GPR54 and GPR54 chimeric receptor transfected 
HEK293-T cells were seeded on cover slips, coated with Matrigel. 48 hours post 
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transfection; cells were visualized using a ZEISS AXIOVERT 200M LSM 510 
Meta confocal microscope at 100x magnification with the assistance of Susan 
Cooper and Prof Dirk Lang of the UCT Confocal and Light Microscope Facility. 
2.2.10 Immunohistochemistry 
Transfected WT-GPR54 and acidic mutant receptors and untransfected HEK293-
T cells were seeded on cover slips, coated with Matrigel. 48 hours post 
transfection; cells were rinsed three times with 0.5 ml PBS. Thereafter, 500 µl of 
a 4% paraformaldehyde (PFA) solution was added to the cover slips to fix the 
cells, and incubated for 15 minutes at room temperature. After three 0.5 ml PBS 
rinses, cells were incubated for 30 minutes in  0.5ml blocking solution (10% FCS 
in PBS) followed by a 2 hour incubation with  50 µl primary antibody diluted in 
blocking solution. Primary antibody solution was then removed and cells were 
rinsed for 3 x 10 minutes in 0.5 ml PBS. The secondary antibody solution (50 µl) 
was added to the cells and incubated in the dark for 45 minutes. Cells were 
rinsed with 0.5 ml PBS and incubated with 1:2000 dilution of DAPI in PBS for 10 
minutes and then rinsed again for 10 minutes with 0.5 ml PBS. Coverslips were 
then mounted on glass slides containing Mowiol mounting solution and stored in 
the dark. Cells were visualised using a ZEISS AXIOVERT 200M LSM 510 Meta 
confocal microscope with the assistance of Susan Cooper and Prof Dirk Lang of 
the UCT Confocal and Light Microscope Facility. 
2.2.11 ELISA Assay 
A modified ELISA, designed by Dr Claire Newton, University of Cape Town 
(unpublished), was performed to measure cell surface receptor expression. 
HEK293-T cells were seeded in matrigel-coated 48-well plates and transfected as 
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described in section 2.2.7.2. 48 hours post transfection, cells in each well were 
rinsed with 400 µl of PBS+ (PBS supplemented with 0.5mM MgCl2 and 0.9mM 
CaCl2) prewarmed to 37°C. Thereafter 150 µl of primary antibody (Monoclonal 
ANTI-FLAG® M2 or Anti-GFP 1:1000 diluted in DMEM supplemented with 10% 
FCS and pre-warmed to 37°C) was added to the cells and incubated for 2 hours 
at 37°C. Cells were then rinsed three times for 5 minutes with 400 µl PBS+ and 
incubated for 1 hour with 150 µl secondary antibody (goat anti-mouse HRP-
conjugated 1:1000 dilution, diluted in DMEM supplemented with 10% FCS). 
Thereafter, three 400 µl PBS+ rinses were performed as before followed by a 
single PBS rinse. 150 µl of 3, 3’, 5, 5’-Tetramethylbenzidine (TMB) substrate 
(0.1mg/ml TMB stock in phosphate citrate buffer, pH5.0, supplemented with 0.2 
µl/ml of 30% H2O immediately before use) was added to the cells and incubated 
in the dark for 20 minutes at room temperature. The reaction was stopped by the 
addition of 150 µl 2M H2SO4 to the cells and the plates were placed on a rocker 
to mix. 150 µl of the supernatant was then transferred to a clear flat bottomed 96-
well plate and absorbance was read at 450 nm using an Anthos 2001 
spectrophotometer.  
To measure total receptor expression, prior to addition of the primary antibody 
solution, cells were rinsed with PBS+ and 300 µl methanol was added to each 
well to permeabilize the cells. Cells were then incubated at -20°C for 10 minutes. 
Thereafter cells were rinsed three times for 10 minutes in 0.5 ml PBS+. 0.5 ml 
blocking solution (DMEM supplemented with 10% FCS and 5% BSA) was added 
to the wells and cells were incubated for 1 hour at 37°C. Cells were then rinsed 
once with 0.5 ml PBS+. The protocol was then continued from the addition of the 
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primary antibody solution as described for measurement of cell surface receptor 
expression. 
2.2.12 Promega CRE-Luciferase Assay  
HEK293-T cells were seeded in 24-well plates coated with matrigel. After 24 
hours, cells were chemically transfected with GPR147 (483.5 ng/well), CRE-Luc 
reporter gene plasmid (483.5 ng/well) and Renilla plasmid DNA (33 ng/well). 
Plates were incubated for 24 hours post transfection in growth media, and then 
rinsed twice with 0.5 ml PBS+. Thereafter 1 ml HEPES-DMEM media (DMEM 
supplemented with 1% pen/strep, 2mM L-glutamine 100 IU/ml penicillin, 100 
IU/ml streptomycin and 10mM HEPES) was added and the cells were grown for 
24 hours. The media was then aspirated and replaced with 0.5 ml of peptide 
dilutions prepared in HEPES-DMEM. Plates were incubated for 6 hours at 37 °C 
after which they were transferred to ice and rinsed with 0.5 ml cold PBS+. 
Promega passive lysis buffer (PLB) was diluted according to the manufacturer’s 
instructions and 20 µl was added to each well. Plates were placed on a shaker at 
high speed for 15 minutes at room temperature.  
Lysates were diluted 1 in 4 with PLB and 20 µl was transferred to a white, flat 
bottomed 96 well plate. Luciferase activity was measured using a Dual luciferase 
reporter gene assay and luminescence was measured with a Lumat LB9501 
luminometer.  
2.2.13 Radiolabelling of peptides 
A modified RFRP3 that includes a Tyrosine (Tyr-Val-Pro-Asn-Leu-Pro-Gln-Arg-
Phe-NH2) was radiolabelled with [I125] using a variation of the Chloramine T 
Chapter 2: Materials and Methods 
58 
 
method. Briefly, 10 µl of peptide (1 µM stock) was re-suspended in  50 µl 0.5M 
phosphate buffer (pH7.4) and mixed with 1mCi carrier-free Na125I (100µCi/µl) . 
Thereafter, 10 µl chloramine T (2mg/ml) was added and the reaction was allowed 
to proceed for 10 seconds. Sodium metabisulfate (2mg/ml) was added 
immediately afterwards to terminate the reaction. The reaction was then loaded 
onto a QAE sephadex G25 size exclusion column and 1 ml fractions were eluted 
in a phosphate buffer containing BSA. 10 µl of the fractions were counted for 1 
minute using a gamma counter (Berthold LB211) to obtain the elution profile and 
identify fractions containing the radiolabelled peptide. 
2.2.14 Whole cell competitive radioligand binding assay 
COS-7 cells were electroporated and seeded in 12-well plates as described 
above. 48 hours post-transfection media was aspirated and cells were incubated 
in 0.5 ml Binding media (DMEM supplemented with 10mM HEPES and 0.1% 
BSA) containing  100,000cpm/well or 50,000cpm/well  [I125]-RFRP3 or [I125]-
KP10, respectively, and increasing concentrations of non-radiolabelled peptide in 
the range of 0-1µM for 4 hours at 4°C. Cells were then rinsed twice with 1 ml cold 
PBS+. Thereafter, 0.5ml 0.1M NaOH was added to the cells and incubated at 
room temperature for 15 minutes in order to lyse the cells. Cell lysates were 
transferred to tubes and radioactivity measured (1min/sample) with a gamma 
counter (Berthold LB211). 
2.2.15 Statistical Analysis 
All data are presented as mean ± standard error of the mean (SEM). Statistically 
significant differences were determined by one-way analysis of variance or paired 
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student’s t-test using Prism 5.0 software (GraphPad Software Inc., San Diego, 
CA) with p<0.05 considered significant.  
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GPCRs are major drug targets. Therefore, much research has been devoted to 
the elucidation of the function and three-dimensional structure of this large family 
of membrane proteins. GPCRs have seven conserved transmembrane (TM) α-
helices which are connected by three extracellular (ECL) and three intracellular 
(ICL) loops. They also have an extracellular N-terminus and intracellular C-
terminus. The ECLs, N-termini, and/or part of the TM α-helical region facing the 
extracellular space are responsible for ligand recognition, whereas the ICL and C-
termini recognize the specific G protein partner required for signal transmission 
within the cell (Palczewski and Orban, 2013). 
Identifying the structural and biochemical requirements of integral domains of 
individual GPCRs assists modelling of the inactive and active receptor 
confirmations, an important factor both for targeted therapeutics and fundamental 
receptor biology. Various strategies are used to gain insight into the structure and 
function of GPCRs, especially since structural information is still relatively limited 
for many GPCRs. Techniques used to elucidate the structural determinants of 
ligand binding and functional activation of receptors include: site-directed  
mutagenesis (SDM), chimeric molecule construction, identification and 
characterization of naturally occurring mutations that alter receptor function, use 
of antibodies directed against receptor epitopes, use of synthetic peptides that 
are homologous to parts of the receptor sequence, and affinity labelling and other 
chemical labelling methods including cysteine modification studies (Kristiansen, 
2004). GPCR crystallization is an important technique that can be used to 
elucidate GPCR structure but it is extremely challenging. GPCRs are unstable 
outside the cell membrane and they are known to adopt many conformational 
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states (Rosenbaum et al., 2009). The relatively unstructured loops add to the 
conformational diversity of GPCRs. The combination of fragility and flexibility is a 
major hurdle which has limited the progress of high-resolution structures. 
However, with developments in engineering, producing and purifying membrane 
proteins, crystal formation, and X-ray diffraction has improved the elucidation of 
GPCR structures. Thus far, 47 structures representing 13 distinct GPCRs have 
been solved, in many cases with resolution of 3 Ǻ or better (Audet and Bouvier, 
2012). 
Mutagenesis is another principal technique for examining GPCR function and 
activation. Through changes to single residues or entire receptor domains 
followed by structure-activity relationship (SAR) studies, insights into which 
residues are involved in ligand binding and/or receptor activation can be gathered 
(Beukers and Ijzerman, 2005,  Martinelli and Tuccinardi, 2008,  Heilker et al., 
2009). SDM combined with bioinformatics techniques utilizing the large number of 
protein sequences in the GPCR family helped bypass the lack of available 
structural data before 2008 (Conner et al., 2010). Of the GPCR structures that 
have been elucidated since 2008, SDM and SAR studies have been used to 
validate these structures and have also provided information on receptors whose 
structures have yet to be elucidated. 
The choice residue for substitution in SDM studies has been predominantly 
alanine, by either individual targeted substitutions or as part of a less-targeted 
alanine scan. Alanine is often chosen due to its small size and lack of reactive 
functional groups which results in no or minor influence on the protein backbone 
(Ahn et al., 2009). Alternatively, conservative amino acid substitutions can be 
made in which residues are substituted with other chemically-similar residues, 
Chapter 3: Role of N-terminus, ECL1-3 and their acidic residues in GPR54… 
 
   
63 
 
theoretically resulting in relatively minor structural/biochemical changes or 
alternatively, non-conservative amino acid substitutions of amino acids with 
different properties can be introduced leading to more profound changes. 
Another method used in structure/function studies is the creation of chimeric 
receptors. Chimeric GPCRs can provide insights into ligand binding factors, G 
protein, and effector coupling, and/or sites necessary for receptor internalization 
and trafficking. Usually, homologous domains are substituted in receptors within 
the same GPCR family. This aims to minimize the disruption of the basic receptor 
structure. Some limitations of the chimeric receptor approach may result in 
chimeric receptors not functioning because of problems in folding and/or 
targeting. Nonetheless, the use of chimeras is an effective tool to elucidate new 
insights into structure/function relationships within the superfamily of GPCRs (Yin 
et al., 2004).  
Glutamate and aspartate are often involved in receptor signalling or binding sites. 
Aspartates and glutamates are negatively charged and polar, and usually are 
located on the surface of proteins, exposed to an aqueous environment. 
Aspartate and glutamate can form ionic bonds (electrostatic bonds) with the 
positive charge on the basic amino acids (histidine, lysine, and arginine) of 
interacting ligands/signalling molecules. Aspartate has a shorter side chain than 
glutamate giving it more rigidity within protein structures. These characteristics 
mean that aspartate is most often involved in ligand binding or signalling sites 
(Betts and Russell, 2003).  
As discussed in the Literature Review, the kisspeptin/GPR54 system was 
recognized as a regulator of reproduction when two groups found that mutations 
Chapter 3: Role of N-terminus, ECL1-3 and their acidic residues in GPR54… 
 
   
64 
 
in GPR54 caused delayed or absent puberty (De Roux et al., 2003,  Seminara et 
al., 2003). Various studies have subsequently emerged investigating the effect of 
kisspeptin on GnRH secretion and the onset of puberty. The GPR54 protein 
shares 45% homology with the galanin family of receptors but does not bind 
either galanin or galanin-like peptide (Lee et al., 1999a). A mutagenesis study on 
the GalR2 subtype identified four residues namely, histidine252 and histidine253 
located in TM6 and phenylalanine264 and tyrosine271 in the ECL3, to be of great 
significance for ligand binding. The N-terminal tail of GalR2 was also shown to 
contribute to ligand binding, and the selective binding of the Gal(2–11) peptide 
includes interaction with the isoleucine256 residue located at the top of TM6 
(Lundstrom et al., 2007). 
Kisspeptin has great therapeutic potential. However, to date, studies have been 
focused on developing kisspeptin agonists/antagonists for therapeutic use and on 
investigation of the naturally occurring mutations on GPR54 and little is currently 
known about the mechanism of binding of kisspeptin to GPR54, information 
which would aid further development of drugs targeting this receptor. Studies 
performed on GPR54 receptor mutations can provide information on the specific 
residues involved in the binding of kisspeptins and the types of inter-molecular 
bonds involved. In this chapter, chimeras and SDM studies will be employed to 
investigate residues important for GPR54 binding and activation. 
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 Determine whether the N-terminus and extracellular loops of GPR54 are 
important for receptor expression,  ligand binding and receptor activation 
 Examine the role of acidic residues of the GPR54 extracellular loops  in 
ligand binding and receptor activation 
 
3.2 Results 
3.2.1 Chimeras of GPR54 and Galanin 2 receptor  
Chimeric substitution is a useful tool to identify important regions for binding and 
activity of GPCRs. In this chapter, chimeric GPR54/galanin receptor 2 (GalR2) 
constructs have been utilised to examine the residues important for 
kisspeptin/GPR54 binding. The extracellular loops (ECL) of GPR54, namely the 
N-terminus and ECLs1, 2 and 3, were independently replaced with corresponding 
sequences from GalR2 (Figure 10). The four resulting chimeric GPR54/GalR2 
constructs (N-terminus-GalR2-GPR54, ECL1-GalR2-GPR54, ECL2-GalR2-
GPR54 and ECL3-GalR2-GPR54) were a gift from Professor Chris Hague of the 
University of Washington (Appendix I).  The wild-type (WT) human (h) GPR54 
was cloned into pEGFP, (to add a C-terminal GFP tag) and the GPR54/GalR2 
chimeras were cloned into pEYFP (to add a C-terminal YFP tag).   
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Figure 10: Amino acid sequence alignment of human GPR54 and Galanin receptor subtype 2. 
Sequences were obtained from the National Center for Biotechnology Information. (GPR54-GenBank: 
AAK83235.1) (GalR2-GenBank: EAW89364.1) Yellow denotes transmembrane domains. – indicates gaps in 
alignment, Acidic amino acids in extracellular domains of GPR54 are denoted in red text. Amino acids of 
GPR54 mutated to alanine are denoted in bold red text. The N-terminal region is situated up-stream of TM1; 
ECL1 is situated between TM2 and TM3, ECL2 between TM4 and TM5, and ECL3 between TM6 and TM7. 
 
 
3.2.1.1 Expression of GPR54/GalR2 receptor chimeras 
Initially the expression of the chimeric GPR54/GalR2 receptors was examined in 
order to ensure that substitution of the chimeric residues did not affect receptor 
expression. WT-hGPR54-GFP and GPR54/GalR2 chimeras were transiently 
transfected into HEK293-T cells. The receptor expression and localisation was 
then determined using live-cell confocal microscopy (Figure 11). The confocal 
microscopy analysis revealed that WT GPR54-GFP and all of the GPR54/GalR2-
YFP receptors were localized to the plasma membrane to some degree and their 
localization patterns were indistinguishable suggesting that the chimeric 
substitutions did not cause trafficking alterations of GPR54. Untransfected 
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HEK293-T cells served as the negative control with no observable fluorescence 
in the untransfected cells. A limitation of the confocal microscopy is that under 
this experimental design, a quantitative analysis of receptor expression could not 
be performed.  
 
 (a) 
         
(b) 
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Figure 11: Live-cell confocal imaging of WT-GPR54-GFP and GPR54/GalR2-YFP chimeras.  HEK293-T 
cells were transfected with (a) WT-GPR54-GFP (b) N-terminus-GalR2-GPR54-YFP (c) ECL1-GalR2-GPR54-
YFP (d) ECL2-GalR2-GPR54-YFP or (e) ECL3-GalR2-GPR54-YFP receptors. 48 hours post transfection 
cells were visualized on a confocal microscope. Left panel represents a merge of fluorescence and 
differential interference contrast (DIC) images. Right panel is fluorescence only. Images representative of 
n=3. 
 
Although the four chimeric receptors appeared to be expressed well and localised 
to the plasma membrane, no comment could be made about the relative levels of 
receptor expression. In order to obtain a quantitative measurement of receptor 
expression levels a whole cell ELISA was performed to measure the total 
receptor expression in the cell. Due to the WT-GPR54-GFP and chimeric-YFP 
receptors having C-terminal GFP and YFP tags, permeabilization of the cells was 
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required in order to allow antibody access. Total receptor expression within the 
cell and not cell surface receptor expression was thus measured. As antibodies 
raised against full-length GFP can also detect YFP and other GFP variants, an 
anti-GFP antibody was used for measurement of all receptors. There was no 
significant difference in total receptor expression between the WT-GPR54-GFP 
and the GPR54/GalR2-YFP chimeric receptors (p>0.05; Figure 12) indicating that 
the chimeras do not affect protein expression. Untransfected cells had no 
measureable absorbance at 450nm. Although total receptor expression is not 
different between the WT GPR54 and chimeric receptors, it should be noted that 
no conclusions can be drawn about their relative levels of cell surface expression 
which is critical for receptor binding and activation.  
 
Figure 12: Relative total cellular expression of WT-GPR54-GFP and GPR54/GalR2-YFP chimeras. 
HEK293-T cells were transfected with WT-hGPR54-GFP, N-terminus-GalR2-GPR54-YFP (NTERM), and 
ECL1-GalR2-GPR54-YFP (ECL1), ECL2-GalR2-GPR54-YFP (ECL2) or ECL3-GalR2-GPR54-YFP (ECL3) 
receptors. 48 hours post transfection cells were permeabilzed with methanol and ELISA performed. 
Absorbance was read at 450 nm. Data are presented as fold increase relative to expression of WT GPR54-
GFP. Representative graph of N=3 and P>0.05 for comparison of chimeric receptors and WT GPR54. The 
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3.2.1.2 Expression and affinity of GPR54-GALR2 receptor chimeras 
The interaction of ligands with their binding site on their cognate receptors can be 
characterized in terms of their binding affinity. Ligands that bind with high affinity 
are as a result of strong intermolecular force between the ligand and its receptor, 
while low-affinity ligands binding involve less intermolecular force between the 
ligand and its receptor. Whole-cell radioligand competition binding assays were 
performed, in which [125I]-KP10 was competed with increasing concentrations of 
unlabelled KP10, in order to determine the affinity of KP10 for the WT GPR54 
and GPR54/Gal2 chimeric receptors. Half maximal inhibitory concentration for 
each receptor, known as the IC50 (the concentration of competing ligand, which 
displaces 50% of the specific binding of the radioligand in a competition assay) 
was determined and used as a measure of relative affinity of KP10 for each 
receptor.  
As whole cell binding assays were performed, it was also possible to compare 
levels of radioligand binding in the absence of competing ligand in order to 
measure relative receptor binding sites on the cell surface.  
An initial radioligand competition binding experiment was performed with COS-7 
cells transfected with WT-GPR54 and WT-GPR54-GFP to validate the assay and 
compare the affinity of tagged and untagged WT-GPR54 (Figure 13). COS-7 cells 
were used as they are more robust and would retain cell numbers better than 
HEK293-T under these experimental conditions. The IC50 value for the WT-
GPR54 (2 nM) and WT-GPR54-GFP (1.5 nM) receptor were not significantly 
different (p>0.05), indicating that the GFP tag did not alter the ligand affinity at 
GPR54. The level of [125I]-KP10 binding in the absence of competing ligand (0) 
was also not significantly different (p>0.05) indicating that the expression levels of 
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WT-GPR54 and WT-GPR54-GFP were also similar and that the GFP tag does 
not affect receptor expression. It should be noted that some non-specific 
radioligand binding was measured (indicated by residual radioactivity after 
dissociation of receptor-bound radioligand with high concentrations of unlabelled 
ligand). This is a common phenomenon observed with radiolabelled KP10 and 
results from non-specific binding of the peptide to the plasticware used in the 






























Figure 13: Radioligand competition binding assay with WT-GPR54 and WT-GPR54-GFP. WT- GPR54 
and WT-GPR54-GFP transfected COS-7 cells were incubated with 50,000cpm/well [125I] KP10 in the 
absence (0) and presence of increasing concentrations of unlabelled KP10 for 4 hours at 4 C. before washing 
and measurement of bound radioligand. N=3. 
 
To test the expression of, and KP10 binding affinity at, the GPR54/GalR2 
chimeric receptors, COS-7 cells were transfected with WT-GPR54-GFP, or the 
GPR54/GalR2 chimeric receptors and radioligand competition binding assays 
were performed. 
At the WT-GPR54 the IC50 measured for KP10 was 9nM (Figure 14), indicating a 
high affinity of KP10 for this receptor and consistent with the data presented in 
Figure 13. There were some differences in affinities (IC50) between the receptors. 
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For example the IC50 of the ECL2 chimera was 2 fold less than WT-GPR54-GFP 
and the ECL1 chimera had a 3 fold higher IC50. However, these differences were 
not significant and the affinity of KP10 for all of the GPR54/GalR2 chimeric 
receptors was not significantly different from its affinity for WT-GPR54-GFP 
(p>0.05; Table 3, Figure 14). However, in the absence of unlabelled KP10, the 
binding of [125I]-KP10 was approximately 50% lower for the GPR54/GlaR2 
chimeras than for WT-GPR54-GFP as indicated by the reduced B0 values (Table 
3, Figure 14), although the BO values measured for each of the chimeras were 
not significantly different from each other (p>0.05). As they have no difference in 
KP10 affinity, this reduction in [125I]-KP10 binding must reflect a reduced cell 
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Figure 14: Radioligand competition binding assay with WT-GPR54 GPR54/GalR2-YFP chimeras. COS-
7 cells were transfected with WT-GPR54-GFP or GPR54/GalR2-YFP chimeric receptors. 48 hours later 
whole cell radioligand competition binding was performed. 50,000cpm/well [125I]-KP10 was incubated with 
cells in the absence (0) and presence of increasing concentrations of unlabelled KP10 for 4 hours at 4 C, 
before washing and measurement of bound radioligand. (a) All receptors. (b) WT-GPR54-GFP only (c) N-
terminus-GalR2-GPR54-YFP chimera (Nterm) only (d) ECL1-GalR2-GPR54-YFP chimera (ECL1) only (e) 
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Table 3: IC50 and B0 values for GPR54/GalR2 chimeras (* p<0.05 for comparison with WT-GPR54-GFP, 
N=3) 
RECEPTOR IC50 ± SEM (nM)  B0 ± SEM (cpm)  
WT-GPR54-GFP 9.17 ± 0.84 4023 ± 634 
Nterm CHIMERA 7.53 ± 3.53 1860 ± 302* 
ECL1 CHIMERA 21.69 ± 6.67 1955 ± 403* 
ECL2 CHIMERA 3.92 ± 1.94 2167 ± 349* 
ECL3 CHIMERA 9.58 ± 6.54 1904 ± 464* 
 
In summary, taken together these data suggest that the N-terminal and ECL 
GPR54-GalR2 chimeras affect GPR54 cell surface expression based on the 
reduced B0 values (Figure 14,Table 3). However, the affinity of the chimera 
receptors is similar to that of WT-GPR54-GFP.  
 
3.2.1.3 Activation of GPR54/GalR2 receptor chimeras 
The GPR54/GalR2 receptor chimeras had similar affinity for KP10 as the WT-
GPR54. We next tested whether the KP10 was able to activate the chimeric 
receptors by determining inositol phosphate (IP) production in cells expressing 
these receptors in response to KP10 stimulation. Briefly, COS-7 cells transfected 
with WT-GPR54-GFP or each of the receptor chimeras and loaded with 
radiolabelled myo-inositol were stimulated with increasing concentrations of 
KP10. Thereafter total IPs were extracted and purified. As myo-inositol is 
incorporated into IP by the cells, measurements of the level of radioactivity of the 
collected samples allowed quantification of the IP produced. 
EMax refers to the maximal response produced by a ligand. A comparison of the 
EMax for KP10 stimulation of IP in cells expressing WT-GPR54-GFP and the 
GPR54/GalR2-YFP chimeras shows that KP10 stimulated the highest IP release 
in cells expressing WT-GPR54-GFP (Figure 15, Table 4). The N-terminus-GalR2-
GPR54-YFP chimera showed the highest KP10 stimulated IP release of all of the 
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chimeric receptors with an Emax 86% of the WT-GPR54-GFP, compared to 56 % 
for the ECL1-GalR2-GPR54-YFP chimera, 38% for the ECL2-GalR2-GPR54-YFP 
chimera and 60% for the ECL3-GalR2-GPR54-YFP chimera. 
EC50 refers to the concentration of ligand that produces 50% of the maximal 
response and can provide information about the ligands potency. KP10 had 
higher potency at the WT-GPR54-GFP receptor than at any of the GPR54/Gal2R-
YFP chimeric receptors with an EC50 of 15 nM (Figure 15, Table 4). At the 
chimeric receptors, KP10 had the highest potency for the N-terminus-GalR2-
GPR54-YFP chimera with only a 9-fold reduction in potency when compared to 
WT-GPR54-GFP. At the ECL1-GalR2-GPR54-YFP, ECl2-GalR2-GPR54-YFP 
and ECL3-GalR2-GPR54-YFP chimeras KP10 displayed a 23-, 31- and a 12-fold 
reduction in potency, respectively, compared to the WT-GPR54-GFP. Therefore, 
this data suggests that the ECLs of GPR54 are important for receptor activation 
while the N-terminus may be less important. 
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Figure 15: IP accumulation assay with WT-GPR54 GPR54/GalR2-YFP chimeras. COS-7 cells 
transfected with GPR54-GFP, N-terminus-GalR2-GPR54-YFP chimera (N-term), ECL1-GalR2-GPR54-YFP 
chimera (ECL1), ECL2-GalR2-GPR54-YFP chimera (ECL2) or ECL3-GalR2-GPR54-YFP chimera were 
stimulated with increasing concentrations of KP10 and assayed for total radioactive inositol phosphate 
accumulation. N=3. 
 






3.2.2 Role of acidic mutations in the ECL domain of GPR54  
The chimeric receptor studies highlighted the importance of the ECL regions for 
GPR54 cell surface expression and receptor activation. The next step was to test 
to role of acidic (aspartate (D) and glutamate (E)) residues within these regions 
for GPR54 receptor expression, affinity and activation. There are 5 acidic 
residues located on the N-terminus and ECLs of GPR54: D31 and D41 (N-
terminus), D112 (ECL1) and E193 and E201 (ECl2). Having shown that the N-
Receptor EC50 ± SEM (nM) Emax ± SEM (cpm)   
WT-GPR54-GFP 14.68 ± 1.26 4175 ± 41 
Nterm chimera 135.33 ± 10.16* 3592 ± 310 
ECL1 chimera 331.9 ± 9.45* 2366 ± 284* 
ECL2 chimera   458.5 ± 3.092* 1566 ± 168* 
ECL3 chimera 176.09 ± 76.42* 2527 ± 653* 
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terminus was not critical for receptor activation, the aspartate residues in position 
31 and 41 of GPR54 were not mutated while the other acidic residues were 
mutated to alanine. GPR54 mutants containing these point mutations (‘acidic 
mutants’) were constructed in pcDNA 3.1 and were tagged at their N-termini with 
a FLAG epitope tag. For comparison, WT GPR54 was also tagged at the N-
terminus with a FLAG epitope tag. 
3.2.2.1 Expression of N-terminal FLAG-tagged GPR54 D112A, E193A and 
E201A receptor mutants  
As the WT-GPR54 and D112A, E193A, and E201A mutants were FLAG tagged, 
this allowed for analysis of receptor localisation/expression by 
immuohistochemical analysis and ELISA. Briefly, for immunohistochemical 
analysis, HEK293-T cells transfected with the WT and mutant receptors were 
fixed 48 hours post transfection, cells were incubated with anti-FLAG antibodies 
and viewed under a confocal microscope. There was no difference in the cellular 
localisation of the three GPR54 mutants when compared to the WT-GPR54 
indicating that these amino acid substitutions did not appear to  affect the cellular 
location of the receptor (Figure 16). 
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(c) 
         
(d) 
         
Figure 16: Cellular location of WT GPR54 and acidic mutants. HEK293-T cells transfected with (a) WT 
(b) D112A. (c) E193A or (d) E201A. GPR54 receptors were fixed and receptors labelled with anti-FLAG 
primary and Alexa 488-conjugated secondary antibodies (red). Cell nuclei were labelled with DAPI (blue) 
Scale bar is 10µm. Left panel: merged image showing distribution of transfected receptors (red), cell nuclei 
(blue and DIC imaging of cells. Right panel: image showing distribution of transfected receptors (red) only. 
Images representative of n=3. 
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As these acidic GPR54 mutants were FLAG-tagged at their extracellular N-
termini, this  enabled the measurement of cell surface receptor expression of 
non-lysed cells using an ELISA to give a quantitative determination of cell surface 
relative receptor expression (Figure 17). There was no statistically significant 
difference in cell surface receptor expression between the WT receptor and any 
of the acidic mutants (p>0.05). The alanine substitutions at residues 112, 193 and 
201 therefore do not have an effect of GPR54 cell surface receptor expression. 
 
 
Figure 17: Relative expression of WT GPR54, D112A, E193A and E201A. HEK293-T cells were 
transfected with WT-hGPR54 and acidic mutation receptors. 48 hours post transfection cells and ELISA 
performed on intact cells. Absorbance was read at 450 nm. Data was normalized against WT-GPR54 and 
represented as fold increase relative to expression of WT GPR54. N=3 and p>0.05 for comparison of 
mutants and WT GPR54.  
 
3.2.2.2 Ligand binding to WT GPR54 and of D112A, E193A and E201A receptor 
mutants  
Having established that the acidic mutants do not affect receptor cell surface 
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competition binding assays were performed on transfected COS-7 cells 
expressing WT GPR54 and the GPR54 acidic mutants. 
Interestingly, the level of [125I]-KP10 binding measured in the absence of 
unlabelled ligand (B0) for the acidic mutants was 50 % lower than for the WT-
GPR54 (Figure 18, Table 5). However, the affinity of KP-10 for WT-GPR54 was 
similar to previous data presented in this thesis (Figure 17, Figure 11 and Figure 
14) with an IC50 of 5nM. The affinities of KP10 for the GPR54 mutant receptors 
with acidic residues of ECL3 substituted with alanine, namely E193A and E201A, 
were similar to that measured for WT-GPR54 (Figure 18), Table 5).  However, 
there was about 30-fold reduction in the IC50 of KP10 for the ECL1 acidic mutant, 
D112A, compared to WT-GPR54 (as IC50 is inversely proportional to affinity). 
However, it should be noted that as the affinity of KP10 for the D112A mutant 
was reduced, it was not possible to fully define the dose response curve and the 
IC50 value presented has been obtained by extrapolation of the data.  
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Figure 18: Radioligand competition binding assay with WT-GPR54 and GPR54 acidic mutants. COS-7 
cells were transfected with FLAG-tagged WT-GPR54 or GPR54 acidic mutants. 48 hours later whole cell 
radioligand competition binding was performed. 50,000cpm/well [125I]-KP10 was incubated with cells in the 
absence (0) and presence of increasing concentrations of unlabelled KP10 for 4 hours at 4 C, before washing 
and measurement of bound radioligand. (a) All receptors. (b) WT-GPR54 only (c) D112A mutant GPR54 only 
(d) E193A mutant GPR54 only (e) E201A mutant GPR54 only. N=3.  
 
Table 5: IC50 and B0 values for GPR54 and GPR54 acidic mutants (* p<0.05 for comparison with WT-
GPR54, N=3) 
Receptor IC50 ± SEM (nM) B0 ± SEM (cpm) 
WT-GPR54 5.33 ± 0.98 4683±818.9 
GPR54-D112A 159.0 ± 32.62* 1985 ± 368.0* 
GPR54-E193A 4.12 ± 1.85 2040 ± 417.5* 
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3.2.2.3 Activation of D112A, E193A and E201A GPR54 receptor mutants  
Inositol phosphate accumulation assays were performed on COS-7 cells 
transfected with WT-GPR54, and D112A, E193A and E201 GPR54 mutant 
receptors in order to establish the effects of the mutations on receptor activation. 
KP10 was most potent at the WT-GPR54 receptor, and produced a robust IP 
response (Figure 19, Table 6). There was a 15-fold decrease in the potency of 
KP10 for the D112A mutant, a 32-fold decrease for the E193A mutant and an 8-
fold decrease for the E201A mutant GPR54 receptors compared to WT-GPR54 
(Figure 19, Table 6). As the affinity of KP10 for the E193A and E201A mutants 
was similar to the WT-GPR54, this suggests that these acidic mutant receptors 
cannot be activated as easily as the WT- GPR54 receptor by KP10. The efficacy, 


































Figure 19: IP accumulation assay with WT-GPR54 and acidic mutants. COS-7 cells transfected with 
WT-GPR54, GPR54-D112A, GPR54-E193A and GPR54-E201A were stimulated with increasing 
concentrations of KP10 and assayed for total radioactive inositol phosphate accumulation. N=3. 
Chapter 3: Role of N-terminus, ECL1-3 and their acidic residues in GPR54… 
 




Table 6: EC50 and Emax values for WT-GPR54 and acidic mutants (* p<0.05 for comparison with WT-
GPR54, N=3)  
Receptor EC50 ± SEM (nM) Emax ± SEM (cpm) 
WT-GPR54 41.82 ± 7.87 37605 ± 8661 
GPR54-D112A 635.9 ± 92.44* 35327 ± 7248 
GPR54-E193A 1353 ± 258.6* 39679 ± 8459 
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The aim of this study was to examine the role of the extracellular domains and 
acidic residues within the extracellular loops of GPR54 in receptor expression, 
ligand-binding affinity and receptor activation. All of the GRP54/GalR2 N-terminal 
and ECL chimeric receptors had expression and localisation indistinguishable 
from that of WT-GPR54 when viewed with the confocal microscope (Figure 11) 
indicating that the chimeric substitutions did not fully impair receptor trafficking to 
the cell membrane. Total receptor expression analysis by ELISA also showed no 
significant difference in receptor expression of WT-GPR54 and the chimeric 
receptors but it was not possible to distinguish between intracellular receptors 
and those present at the cell surface (Figure 12). However, in the binding assays 
(Figure 14), cell surface expression of all of the GPR54/GalR2 chimeras 
appeared to be reduced by 50 % compared to WT-GPR54 as indicated by the 
reduced B0 values. Therefore, the chimera substitutions do not impair  receptor 
expression but do appear to have some effect on trafficking of the receptors to 
the plasma membrane.  
The affinity of KP-10 (IC50) for the GPR54/Gal2R chimeric receptors, although 
slightly altered were not significantly different from WT-GPR54. The similar 
affinity between WT-GPR54 and the chimeric receptors suggests that these 
domains are not essential for KP10 binding to GPR54.  
None of the chimeric receptors were able to mimic the robust IP response of WT-
GPR54 to stimulation by KP10 and the potency (EC50) of KP10 at all of the 
chimeric receptors was significantly lower than that for WT-GPR54 (Figure 15). 
The N-terminal chimera had higher potency than the ECL chimeras and was also 
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able to stimulate an IP response of 86% of that seen at the WT-GPR54, 
indicating that the role of the N-terminal region in receptor activation is less 
critical that the ECL regions. KP10 had the most reduced potency and efficacy 
(Emax) at the ECL 2 chimera. The ECL2 region of GPR54 could thus play a critical 
role in receptor activation. ECL3 and ECL1 of GPR54 could also be important for 
receptor activation as a 12-fold and 23-fold decrease in KP10 potency, 
respectively, was observed for these chimeric receptors. The ECLs of GPCRs 
have high degrees of variability that differ in length and sequence. The roles of 
the extracellular residues of GPCRs have not been as well defined compared 
with residues in transmembrane helices. ECL2 has been the focus of research, 
because the x-ray structure of bovine rhodopsin revealed that ECL2 projects into 
the binding crevice within the transmembrane bundle. It has also been found to 
be directly involved in ligand binding and may contribute to G protein subtype 
selectivity (Shi and Javitch, 2004,  Bokoch et al., 2010). ECL1 has also been 
shown to contribute to receptor activation for the A2BAR (Peeters et al., 2011). 
Consistent with the research cited, the ECL2, and to a lesser extent ECL3 and 
ECL1, of GPR54 appears to influence receptor activation.   
The chimera data indicated that the N-terminus was less important that the ECLs 
for receptor signalling. In contrast, the N-terminal tail of GalR2 has been shown to 
be involved in ligand binding, possibly through forming a disulfide bond with ECL3 
(Lundstrom et al., 2007). As the N-terminal region of GPR54 appeared to be less 
important than the ECL regions for receptor activation, only the ECL regions were 
studied in more detail.  
There are five acidic residues on the extracellular domains of GPR54. The three 
acidic residues located on the ECLs of GPR54 D112, D139 and E193 were 
Chapter 3: Role of N-terminus, ECL1-3 and their acidic residues in GPR54… 
 
   
88 
 
substituted with alanine, to form the following receptor mutants, D112A, D139A 
and E193A. A qualitative confocal analysis of the expression pattern of these 
GPR54 acidic mutants (Figure 16) and a quantitative ELISA measuring receptor 
cell surface expression (Figure 17) showed that all three acidic mutants were 
expressed at the cell surface and that there was no significant difference in their 
localisation or expression level when compared to the WT-GPR54. These 
mutations therefore did not affect receptor expression of trafficking to the cell 
surface. 
As with the chimeric receptors, binding assays using the acidic mutant receptors 
indicated that receptor expression (B0) was reduced by approximately 50% when 
compared to WT-GPR54 (Figure 18). KP10 had a similar affinity for the E193A 
and E201A mutant receptors compared to WT-GPR54 therefore the observed 
reduction in B0 was not an indirect result of reduced radioligand affinity. At the 
D112A mutant receptor, KP10 showed a significant 30-fold decrease in affinity. 
The acidic residues on ECL2 namely E193A and E201A are therefore not critical 
for ligand binding while the ECL1 acidic residue, D112A, may contribute to ligand 
binding. Additional mutational studies of this residue would aid in clarifying the 
effect of this acidic residue in position 112 on GPR54 binding. 
In a receptor activation assay, KP10 had a 15-fold lower potency at the D112A 
mutant compared to WT-GPR54 reflecting the decreased affinity of KP10 for this 
mutant (Figure 19).  It is interesting to note that there was only an 8-fold decrease 
in potency of KP10 for the E201A mutant receptor compared to the large 32-fold 
decrease observed for the E193A mutant receptor (Figure 19). Both these mutant 
receptors are located on ECL2 and although neither had altered KP10 affinity, 
they have different effects on receptor activation. Despite the differing effects of 
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the mutations on KP10 potency, all the acidic mutant receptors were able to elicit 
a maximum IP response similar to that of WT-GPR54. It is possible that the 
reduced receptor expression could contribute, in part, to the decrease in KP10 
potency observed for the acidic mutant receptors due to the presence of ‘spare 
receptors’. However, as the presence of spare receptors would result in the 
observed KP10 potency for the WT GPR54 being higher than its observed 
affinity, there is no evidence for spare receptors in this system. While the reduced 
potency of KP10 for the D112A mutant can be attributed to a reduced binding 
affinity at this mutant, for the E193A and E201A mutant receptors, which had 
similar KP10 affinity as WT-GPR54, the reduced potency of KP10 could indicate 
that these residues play a role in receptor activation. This would be consistent 
with the ECL2 chimera receptor findings further highlighting the importance of this 
domain for receptor activation. 
The function of extracellular charged residues that are highly conserved 
throughout a subfamily of peptide GPCRs has been investigated using the 
vasopressin receptor 1a (V1aR). It was found that Asp112 (ECL1) in the V1aR 
was largely conserved throughout the neurohypophysial hormone receptor family. 
Several amino acid substitutions, [D112A]V1aR, [D112E]V1aR, and 
[D112K]V1aR had little effect on receptor function but introduction of R112 (i.e. 
replacement of an acidic reside with a basic residue), resulted in  impaired 
agonist binding and signalling (Hawtin et al., 2006). [The D112A]V1aR had similar 
ligand affinity but a 3-fold reduction in ligand potency compared to the WT 
receptor. This data is similar to the data obtained for D112A mutant of GPR54. In 
ECL2 of the V1aR, a [D204A]V1aR substitution had a marked effect on receptor 
function, with a decrease in ligand affinity, and impaired ligand potency being 
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observed (Hawtin et al., 2006).  Studies performed on human neuropeptide Y 
receptor also indicated that acidic residues namely, D194A, D200A, D205A and 
D287A, impaired ligand binding (Walker et al., 1994) further highlighting the 
importance of these acidic residues in GPCR function. 
In summary, these data indicate that the ECLs of GPR54 and acidic residues 
contained within them contribute to cell surface receptor expression (as 
measured in binding assays) and play a role in receptor signalling. The potential 
for ECL1 to be involved in ligand binding exists as it was the only chimera to 
show a slight decrease in KP10 affinity when compared to WT-GPR54.  The 
D112A receptor mutant, located on ECL1 also appears to be involved ligand 
binding as it too had lower affinity when compared to WT-GPR54. The ECL2 
chimera implicates this domain as having a critical role in receptor activation and 
both the acidic mutants of ECL2 corroborate this theory as they too had reduced 
KP10 potency. 
 A more comprehensive mutagenesis study should now be undertaken to 
investigate the role of other residues in the ECLs as well as additional mutations 
of the acidic residues to establish which amino acids can improve or abolish 
GPR54 receptor expression and binding. Further structure-function studies would 
expand the current knowledge of GPR54 and KP10 interactions and greatly aid in 
the design of new drugs with increased affinity and selectivity, thereby potentially 
decreasing the occurrence of off-target side-effects and potentially reducing the 
therapeutic doses required. This would be of great importance for GPR54 as its 
implications in reproductive development puberty and pregnancy make it an 
important target for design of novel therapeutics. 
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RFamide peptides are biologically active peptides with an RFamide motif at their 
C terminus and can be found in the animal kingdom from invertebrates to 
mammals. The members of the RFamide peptide family have rich therapeutic 
potential as they are involved in multiple regulatory systems. Many of the ‘orphan’ 
GPCRs have been found to be the receptors for mammalian RFamides. GPR54 
and its cognate ligand kisspeptin are one example. Cases of extensive overlap 
exist in the binding affinity between different RFamides and their receptors. This 
is believed to be because receptor selectivity of these compounds seems to be 
determined primarily by a few relatively conserved amino acids at the C-terminus 
of the ligand (Yoshida et al., 2003). This ligand promiscuity is a major stumbling 
block in investigations of the distinct roles for single RFamide peptides. 
The NPFF receptors (GPR147/GPR74) have a number of endogenous ligands, 
including NPFF/NPAF (derived from the NPFFA precursor protein) and 
RFRP3/RFRP1 (derived from the NPFFB precursor protein). In addition to these 
cognate ligands, a number of other neuropeptides  show considerable affinity and 
agonistic activity at these receptors (GPR147 and GPR74) (Engström et al., 
2003). The promiscuity of these two receptors is not restricted to RFamide 
peptides, because they also interact moderately with NPY, a RYamide (Bonini et 
al., 2000,  Engström et al., 2003). KP10, the cognate ligand for GPR54, has also 
been described to target the NPFF receptors with nanomolar affinity (Oishi et al., 
2010). In addition, GPR147/GPR74 themselves share high affinities to their 
endogenous ligands (Oishi et al., 2010). Due to the promiscuity of the 
endogenous ligands, the development of selective agonists and antagonists is 
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required in order to explore the distinct mechanism of the diverse 
pharmacological effects of these peptides and receptors. 
Many SAR studies have been performed on the NPFF receptors and interactions 
with their ligands. Interactions of endogenous RFamide peptide hormones, NPFF, 
NPAF, RFRP3, and RFRP1 with GPR147 and GPR74 have been investigated. 
Systematic substitutions were made using NPFF as a template to determine the 
importance for particular residues for receptor activation. NPFF is able to activate 
GPR147 but additional peptide modifications result in decreased potency.  A SAR 
study has also been performed using bovine RFRP3. Endogenous bovine RFRP3 
is composed of 28 amino acids. This is 10 amino acids longer than endogenous 
rat RFRP3 (Ukena et al., 2002), and 20 amino acids longer than human RFRP3 
which is just eight amino acids long. Yoshida et al.(2003)  investigated the effects 
of truncated bovine RFRP3 with regards to binding affinity and receptor activation 
(Table 7). Binding affinity was retained for all the peptides tested at GPR147 and 
activation was only impaired for a terminal tetrapeptide (PQRFNH2). In contrast, 
these modified bovine RFRP3 peptides were able to bind but not activate GPR74 
(Yoshida et al., 2003). 
Yoshida et al.(2003) also found that three amino acid residues, namely PNL in 
RFRP3 and LFQ in NPFF, at the N terminus of PQRF-NH2 played important roles 
for receptor specificity determination of the ligands, but also for stimulation of full 
receptor activation. Of these three amino acid residues, proline (P) and leucine 
(L) of RFRP3 were found to be especially important for the interaction of this 
ligand with GPR147. Their data further indicated that in vitro, short RFRP3 
peptides (minimally PNLPQRF-NH2) exhibited interactions with GPR147 and 
GPR74 as effectively as the full-length endogenous bovine RFRP3 (Yoshida et 
Chapter 4: GPR147 interactions with select RFamides and RFRP3 analogs 
94 
 
al., 2003). Important residues such as the proline, leucine and PQRF-NH2, are 
conserved between human, bovine, rat and mouse species of the ligand (Hinuma 
et al., 2000,  Fukusumi et al., 2001), whereas the N-terminal portion shows 
diversity in both length and sequence between species. 
Table 7: Comparison of RFRP3 interactions with GPR147 and GPR74 by competitive binding and 
















SAGATANLPLRSGRNMEVSLVRRVPNLPQRF-NH2 1.3             4.8 16 780 
hRFRP3-
28 
ATANLPLRSGRNMEVSLVRRVPNLPQRF-NH2 1.1 5.1 14 520 
bRFRP3-
28 
AMAHLPLRLGKNREDSLSRWVPNLPQRF-NH2 1.6 6.4 7.0 290 
hRFRP3-
17 
NMEVSLVRRVPNLPQRF-NH2 3.4 6.8 18 730 
hRFRP3-
8 
VPNLPQRF-NH2 1.2 4.1 150 ˃1000 
hRFRP3-
7 
PNLPQRF-NH2 0.62 3.0 110 ˃1000 
hRFRP3-
6 
NLPQRF-NH2 2.6 28 230 ˃1000 
hRFRP3-
5 
LPQRF-NH2 2.1 51 76 ˃1000 
hRFRP3-
4/ NPFF4 
PQRF-NH2 15 ˃1000 26 ˃1000 
 
In the studies described in this Chapter , the effects of different RFamide and 
RFamide-related peptides on GPR147 receptor binding and activation were 
investigated. SAR studies were also performed on human RFRP3 to further 
characterize important residues for binding an activation of GPR147. As 
discussed in the Literature Review, like GPR54, GPR147 (but not GPR74) has 
been implicated in modulation of GnRH activity and therefore has a potentially 
important role in the regulation of reproduction and fertility. Therefore, this study 
was focussed on the GPR147 receptor. 




 To investigate the binding affinities of  selected RFamides at the GPR147 
receptor in order to establish a ligand selectivity profile for this receptor 
 To investigate the SAR of different modified RFRP3 analogs with respect 
to their binding and activation of the GPR147 receptor in order to identify 
key residues required for these processes  
4.2 Results 
4.2.1 Iodination of RFRP3 and competitive binding assays of GPR147 with 
selected RFamide peptides  
The chloramine T method was used to radiolabel a modified form of human 
RFRP3 which had a tyrosine reside added to the N-terminal in order to permit 
iodination (Tyr-hRFRP3). The resulting  [125I]-hRFRP3 was purified using size 
exclusion chromatography and 1 ml fractions were collected and radioactivity 
measured in order to identify fractions containing the radiolabelled peptide 
(Figure 20). Fractions with the highest radioactivity (cpm) were then tested on 
COS-7 cells transiently, expressing murine GPR147 in order to identify fractions 
containing the highest concentration of peptide (determined as the fold difference 
between the level of binding measured in the absence (B0) and presence of 1µM 
RFRP3 (NSB) to use in subsequent binding experiments (Figure 21). From these 
data, fractions 15-18 were used in subsequent competitive binding assays. This 
procedure was also used for all subsequent iodination’s in order to obtain the 
fraction/s with the greatest displacement potential. 
 




Figure 20: Typical elution profile for hRFRP3 iodination. 1 ml fractions were collected after which 




Figure 21: Typical displacement data for [125I]-RFRP3 fractions. Fractions with the highest level of 
radioactivity were evaluated for their ability to be displaced by 1 µM RFRP3. Sample 1-fraction 12-13; 
Sample 2- fraction 9-11; sample 3- fraction 14; sample 4- fraction 21; sample 5-fraction 22; sample 6- 15-16; 
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Several RFamide and RFamide-related peptides (Table 8) were then tested in 
radioligand competition binding studies with [125I]-RFRP3 in order to investigate 
their affinity for GPR147. In all cases, the level of radioligand binding in the 
absence of competing peptide (B0) was not significantly different (p>0.05), 
indicating that GPR147 receptor expression was similar, and the number of 
receptors available to the ligands was the same (Table 9).  The endogenous 
GPR147 ligands, RFRP1 and RFRP3, had similar binding affinities (Figure 22, 
Table 9). KP10 had 3-fold lower affinity for GPR147 than RFRP1 and RFRP3 
(Figure 22; Table 9) and was also able to fully displace [125I]-RFRP3, indicating 
that these peptides are interacting with the same population of receptors. RFRP2, 
PPY, CCK and NPY were not able to displace the bound [125I]-RFRP3 at the 
concentrations tested and determination of IC50 values was not possible. 
Therefore, no further studies were performed using these RFamide-like peptides 
due to their low binding affinities.  









































Figure 22: Radioligand competition binding assay for WT-GPR147 with different RFamides. COS-7 
cells were transfected with WT-GPR147. 48 hours later whole cell radioligand competition binding was 
performed. 100,000cpm/well [125I]-RFRP3 was incubated with cells in the absence (0) and presence of 
increasing concentrations of unlabelled peptide for 4 hours at 4 C, before washing and measurement of 
bound radioligand. N=3. 
 
 
 Table 9: IC50 and B0 values for GPR147 with different RFamides (* p<0.05 for comparison with 
RFRP3, N=3). 
Peptide IC50 ± SEM (nM) B0 ±SEM (cpm) 
RFRP3 14.61 ± 9.08 8067 ± 1382 
KP10 51.00 ± 17.63 8956 ± 1590 
RFRP1 12.63 ± 6.75 8390 ± 1545 
RFRP2 ND 10052 ± 129 
PPY ND 9727 ± 710 
CCK ND 9612 ± 504 
NPY ND 9119 ± 1218 
                                     ND=not displaced 
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In summary, although RFamides share similar peptide characteristics, not all 
peptides have high affinities for other receptors within the RFamide family. KP10 
displayed 3-fold lower affinity for GPR147 than RFRP3/RFRP1 and none of the 
other peptides tested were able to significantly displace [125I]-RFRP3 from the 
receptor. Further SAR affinity and activity studies with kisspeptin/kisspeptin 
analogs and the GPR147 receptor were subsequently investigated and are 
described in Chapter 5. 
4.2.2 SAR of RFRP3 analogs 
4.2.2.1 Binding affinity of RFRP3 analogs at GPR147 
Peptide analogs of RFRP3, developed as potential agonist or antagonists for the 
GPR147 receptor, were tested for their ability to bind GPR147. Radioligand 
competition binding experiments with [125I]-RFRP3 were again used to measure 
affinities of the different analogs. The seven analogs tested (Table 10) included 
peptide 251 (a short acetylated RFRP3), peptide 252 (with a D-tryptophan 
substitution at position 6), peptide 253 (with an asparagine substitution at position 
6), peptide 254 (with a D-alanine substitution at position 6), peptide 255 (with an 
alanine substitution at position 3), peptide 256 (with an alanine substitution at 
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Table 10: Sequence alignment of RFRP3 analogs. Changes to the endogenous sequence are 
indicated in bold. 
Peptide name/amino 
acid position 
1 2 3 4 5 6 7 8  
RFRP3 V P N L P Q R F NH2 
251 Ac N L P Q R F NH2 
252 V P N L P (D)-W R F NH2 
253 V P N L P N R F NH2 
254 V P N L P (D)-A R F NH2 
255 V P A L P Q R F NH2 
256 V P N L P A R F NH2 
257 V P A L P A R F NH2 
                 Ac=acetylated 
The endogenous ligand, RFRP3 fully displaced the radioligand binding and had 
an affinity (IC50) of 5.14 nM (Figure 23, Table 11). All of the modified analogs 
tested displayed some binding impairment. Some of the analogs had moderate 
decreases in affinity such as peptide 251, the truncated RFRP3, which had 8-fold 
lower affinity than RFRP3 and peptide 255 (Ala3 RFRP3) which displayed 10-fold 
lower affinity than RFRP3. The alanine substitution in position 6 (peptide 256) 
resulted in a 30-fold reduction of affinity.  The substitution of D-Tryptophan or 
asparagine into position 6 (peptides 252 and 253) reduced binding affinity by 
greater than 100-fold compared to RFRP3. The double alanine substitution (pep 
257) also had a 75-fold reduction in affinity. The severe reduction in binding 
affinity of peptides 252 and 257 meant that full displacement could not be 
achieved and IC50 values were calculated by extrapolation of the data. In the 
case of peptide 253 an accurate curve could not be fitted, preventing calculation 
of IC50. The D-alanine substitution in position 6 (peptide 254) had the most 
severe effect on ligand affinity, and this ligand was unable to significantly displace 
the radiolabelled [125I]-RFRP3.  Taken together these results indicate that glycine 
in position 6 plays an important role in ligand binding and changes to asparagine 
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Figure 23: Radioligand competition binding assay with WT-GPR147 and RFRP3 analogs. COS-7 cells 
were transfected with WT-GPR147. 48 hours later whole cell radioligand competition binding was performed. 
100,000cpm/well [125I]-RFRP3 was incubated with cells in the absence (0) and presence of increasing 




Table 11: IC50 and B0 values of RFRP3 analogs. (* p<0.05 for comparison with RFRP3, N=3) 
Peptide IC50 ± SEM (nM) B0 ± SEM (cpm) 
RFRP3  5.14 ± 0.23 6098 ± 1959 
251 Ac-3-8-RFRP3 39.45 ± 3.74* 6128 ± 2125 
252 D-W6-RFRP3 999.3 ± 674.5* 6363 ± 1847 
253 N6-RFRP3 ND 6399 ± 1891 
254 D-A6-RFRP3 137.9 ± 126.2* 6590 ± 2141 
255 A3-RFRP3 55.35 ± 16.2* 6396 ± 1920 
256 A6-RFRP3 173 ± 10.6* 6396 ± 1826 
257 A3A6-RFRP3 384.2 ± 190.8* 6746 ± 1785 
                  ND= not displaced; Ac=acetylated 
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4.2.2.2 Activation of GPR147 by RFRP3 analogs 
GPR147 couples to the Gi/o family of G proteins which, when activated, inhibit AC 
stimulated cAMP accumulation. Therefore, in order to measure receptor 
activation by the RFRP3 analogs, CRE-luciferase assays were used. AC was 
directly stimulated with forskolin (FSK), and the inhibition of FSK-induced cAMP 
production by the analogs was measured using a CRE-luciferase reporter (a 
luciferase gene under the control of a cAMP response element). Briefly, 
transfected HEK293-T cells were stimulated with 1µM FSK and 1µM peptide for 
five hours. Thereafter, CRE-luciferase luminescence was measured. To 
normalise for differences in transfection efficiencies and cell number, the CRE-
luciferase signal was normalised against the luminescence measured for a co-
expressed Renilla luciferase (constitutively expressed). 
RFRP3 stimulation elicited a significant reduction in FSK induced cAMP 
production (Figure 24). Peptides 251, 253, 255 and 256 also significantly reduced 
cAMP production to a level similar to that seen for the control RFRP3. However, 
peptides 252, 254 and 257 did not decrease FSK cAMP production and thus did 
not appear to activate the receptor, probably due to their low binding affinity. 
These results indicate that glutamine in position 6 is not critical for receptor 
activation as some substitutions are tolerated in this position. The alanine 
substitution in position 3 (peptide 255) also did not impair receptor signalling 
indicating that this asparagine also does not play a significant role in receptor 
activation. The double substitution with alanine in positions 3 and 6 (peptide 257) 
did result in reduced receptor activation. Therefore, although these residues are 
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not essential for receptor activation on their own, in combination, the disruption in 
binding affinity of this peptide results in decreased receptor activation.  
In summary, these data show that the N terminus of the peptide is not essential 
for receptor binding or activation as peptide 251 displayed only moderately 
reduced affinity and was also capable  to activate GPR147.  Glutamine in position 
6 of hRFRP3 appears to be important for receptor binding as some substitutions 
at this position severely reduced binding affinity (peptides 252, 253 and 254). 
When alanine was substituted at positions 3 or 6 only a small impairment in 
binding affinity was observed, however the analog containing both substitutions 
was severely impaired. Interestingly, although peptide 253 had severely reduced 




Figure 24: Forskolin inhibition assay of GPR147 with RFRP3 analogs. CRE-Luc assay was performed 
on GPR147 transfected HEK293-T cells incubated for 5 hours with 1 µM forskolin (FSK) and 1 µM peptide. 
Cell lysates were read on a luminometer and normalized with Renilla firefly. * p˂0.05. RLU= relative 
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4.3 Discussion  
The aim of this chapter was to investigate the binding affinity of select RFamides 
at GPR147 and to characterize novel RFRP3 analogs with regards to binding and 
activation of GPR147 in order to identify characteristics that determine the 
binding affinity and/or activity at this receptor.   
The RFamide peptides share many features amongst themselves and with other 
members of the neuropeptide family. Therefore, it is possible that these short 
peptides may be recognized by more than one neuropeptide receptor. Some 
RFamides have been shown to have affinity and agonistic activity to the preferred 
receptors for NPFF family members, namely GPR147 and GPR74 (Engström et 
al., 2003). These two receptors may not be limited to interacting with RFamide 
peptides, since there is some evidence that they may also interact with orexin 
and CCK peptides, whose function of food intake regulation overlaps with that of 
RFamides (Engström et al., 2003,  Bonini et al., 2000). However, the affinity and 
activity of these peptides appears to be more prominent at GPR74 than GPR147 
although these two receptors are classified together as NPFF receptors. In order 
to determine the ligand specificity of GPR147 the binding of several different 
neuropeptides whose receptors shared 30 % homology with GPR147 was 
examined in this study.  
The IC50 values obtained for RFRP1 and 3 at GPR147 in this study were 
comparable with those obtained in published reports (Yoshida et al., 2003,  
Bonini et al., 2000,  Mollereau et al., 2002). The RFamide and RFamide-related 
peptides, NPY, CCK and PPY displayed little/no displacement/low affinity for the 
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GPR147 receptor in this study. Previous studies have also reported that NPY did 
not recognize GPR147 (Mollereau et al., 2002).  
In contrast to RFRP1 and RFRP3, RFRP2 did not displace [125I]-RFRP3 from the 
GPR147 receptor indicating little/no affinity of this ligand for this receptor. In 
rodents only two RFRPs are encoded, namely RFRP1 and RFRP3 while the 
RFRP2 sequence has been lost (Ubuka et al., 2012). This absence of RFRP2 in 
the rodent preproprotein sequence indicates that RFRP2 most likely has no 
significant function in mammals. In humans it has been also previously been 
shown that RFRP2 does not exhibit any activity at GRP147 when compared to 
RFRP1 and RFRP3 (Yoshida et al., 2003), thus confirming the findings of this 
study that RFRP2 does not interact with GPR147. 
 KP10 was found to have high affinity for the GPR147 receptor. This is consistent 
with results obtained by Oishi et al.(2010)  who found that KP10 exhibited potent 
binding and activation of GPR147 and GPR74 (Oishi et al., 2010). Sequence 
alignment of RFRP3 and KP10 show that the asparagine (position 3 RFRP3) and 
the serine (position 4 KP10) are weakly similar whilst the leucine (position 4 
RFRP3) and phenylalanine (position 5 KP10) share strong hydrophobic 
properties. These shared properties could contribute to KP10 interactions with 
GPR147 since these residues were found to be critical for RFRP3 interaction with 
GPR147 (Yoshida et al., 2003) The relationship between kisspeptin and GPR147 
will be explored further in subsequent chapters.  
Modified RFRP3 analogs were then examined in order to identify residues that 
could play a role in binding and receptor activation. A truncated RFRP3 (peptide 
251) retained moderate affinity (7-fold less than RFRP3) and was able to activate 
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GPR147. It has been previously reported the minimum sequence needed to bind 
and activate the GPR147 receptor was the seven-amino acid length C-terminal 
peptide of RFRP-3 (hRFRP3: PNLPQRF-NH2) (Yoshida et al., 2003). However, 
the present study demonstrates that a shorter acetylated six-amino acid peptide 
(peptide 251) is also able to bind and activate this receptor.  
Amino acid orientation within peptide ligands is important for receptor binding. 
Peptides 252 and 254 have D-isomers replacing the glutamine in position 6 of 
RFRP3. These peptides could not displace the radiolabelled RFRP3 and thus 
displayed low binding affinity and were unable to activate the GPR147 receptor. It 
is possible that these D-isomers restrict the ligands access to the binding site and 
result in poor affinity.  Interestingly, an asparagine substitution at position 6 
(peptide 253) also showed low affinity but was still able to activate the receptor 
significantly, suggesting that, once bound, this ligand may be able to induce 
receptor activation more effectively/potently than RFRP3 or that there is a high 
degree of ‘spare receptors’ in this system meaning that only relatively small 
concentrations of ligand are required to produce a large response. Further 
examination of the receptor-ligand interactions of this analog would be required 
before strong conclusions could be drawn. For example, it would be pertinent to 
perform receptor signalling assays with a range of peptide concentrations in order 
to determine the potency of this analog. Substitution of an alanine in position 6 
(peptide 256) also resulted in a reduction in ligand affinity. However this peptide 
was still able to significantly activate the GPR147 receptor. The SAR studies 
performed on hRFRP3 thus revealed that the Gln in position 6 was important for 
receptor affinity but not for receptor activation. Thus the amide functional group 
Chapter 4: GPR147 interactions with select RFamides and RFRP3 analogs 
107 
 
present in glutamine appear to represent an important group in the interaction of 
this ligand with GPR147.  
Another analog, in which asparagine in position 3 was replaced (peptide 255), 
showed a 10-fold reduction in affinity compared to RFRP3. However, this analog 
was still able to activate the receptor; again indicating that asparagine in position 
3 of RFP3 plays a greater role in ligand binding than receptor activation. A double 
substitution analog with alanine in positions 3 and 6 of RFRP3 (peptide 257) 
resulted in further decreased affinity compared to the analogs with the equivalent 
single alanine substitutions (peptides 255 and 256) indicating an additive effect of 
these substitutions. Unlike the analogs with equivalent single alanine 
substitutions, this doubly substituted analog was unable to decrease FSK induced 
cAMP production, most likely due to its more severe disruption in ligand binding.  
Studies performed on bovine and human RFRP3 have suggested that three 
amino acid residues in position 2, 3 and 4 (PNL), in combination with the last four 
residues of RFRP3 (PQRF-NH2) are important for determining receptor 
specificities as well as receptor activation. The authors further found that the 
proline (P) and leucine (L) of the PNL group were more critical for interaction with 
GPR147 (Yoshida et al., 2003). The data in the present study have indicated a 
strong role of glutamine 6 and to a lesser extent, asparagine 3 in ligand binding to 
GPR147, but not receptor activation. Further SAR studies on RFRP3 utilising 
other analogs in which different residues have been substituted will help elucidate 
the residues critical for ligand binding and receptor activation.  
While the potential for cross-talk and ligand promiscuity exists within the RFamide 
receptor family, we have found that GPR147 has relatively high ligand-specificity. 
Chapter 4: GPR147 interactions with select RFamides and RFRP3 analogs 
108 
 
Aside from its cognate ligands (RFRP3 and RFRP1), only KP10 bound the 
GPR147 receptor with high affinity 
The GPR147/RFRP3 system is emerging as an important player in reproduction. 
Greater understanding into ligand receptor interactions will aid in unravelling 
pathways activated by RFRP3/GPR147 and contribute to a greater understanding 
of receptor function and the data presented in the present study represent an 
important step on the path towards this goal.
Chapter 5: GPR147 interactions with selected kisspeptin analogs   
109 
 
Chapter 5: GPR147 interactions with 
selected kisspeptin analogs 
 
5.1 Introduction ........................................................................................................ 110 
   5.1.1 Aims ............................................................................................................. 111 
5.2 Results ............................................................................................................... 111 
   5.2.1 Binding affinity of kisspeptin analogs at GPR147 ........................................ 112 
   5.2.2 Activation of GPR147 by kisspeptin analogs ............................................... 114 
5.3 Discussion ......................................................................................................... 118 
  




Gonadotropin secretion is regulated by neuropeptides upstream of GnRH in the 
hypothalamic-pituitary-gonadal (HPG) axis. One such neuropeptide is kisspeptin, 
a member of the RFamide family of neuropeptides (Oakley et al., 2009). It has 
been found that stimulation of their cognate receptor, GPR54, by kisspeptins 
promotes the release of gonadotropin-releasing hormone (GnRH) from GnRH 
neurons, which, in turn, increases the plasma level of gonadotropins and initiates 
the onset of puberty (Dhillo et al., 2005,  Shahab et al., 2005).  
In 2000, Tsutsui et al identified an RFamide related peptide that inhibited 
gonadotropin secretion in quail brains and termed it gonadotropin-inhibitory 
hormone (GnIH) (Tsutsui et al., 2000). Another group later identified a 
mammalian RFamide precursor protein in humans using bioinformatics, that was 
predicted to give rise to two mature RFamide peptide GnIH homologs,  RFRP1 
(also known as NPSF) and RFRP3 (also known as NPVF) (Hinuma et al., 2000). 
The precursor protein also encodes another related peptide with an RS-amide C-
terminus (RFRP2), although further biochemical characterisation has revealed 
that RFRP2 is not produced in vivo (Yoshida et al., 2003,  Ukena et al., 2003). 
GPR147 and GPR74 (which couple to the Gi/o family of G proteins) have been 
identified as the cognate receptors for the RFRPs.  
As discussed earlier, RFRPs and KP10 appear to have opposing actions on the 
regulation of the HPG axis and there is evidence of interplay between these two 
signalling systems. The RFRP peptides share characteristics with many other 
members of the neuropeptide family, including the kisspeptins, thus these 
peptides have the potential to be recognized by/recognize each other’s receptors. 
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Indeed, Lyubimov et al. reported moderate activation of GPR74 by endogenous 
KP-13 and KP-14 (Lyubimov et al., 2010) and in GPR147 expressing CHO cells, 
KP-54 and KP-10 both activated GPR147, leading to a reduction in FSK induced 
cAMP production (Oishi et al., 2010). 
In the present study, the relationship between kisspeptin analogs and the RFRP 
receptor GPR147 will be studied.  
5.1.1 Aims 
 To investigate the binding and activation of GPR147 by kisspeptin analogs 
in order to try to better elucidate the mechanism of interplay between these 
two important regulators of reproduction, and to identify analogs with the 
potential to acts as novel GRP54/GRP147 regulators that could be used 
as tools to aid further examination of these important signalling pathways 
and/or used for development of novel therapeutic interventions targeting 
these receptors.   
5.2 Results 
Kisspeptin has previously been shown to bind GPR147 (Oishi et al., 2010) and 
the data presented in Chapter 4 of this thesis is consistent with those 
observations. In pursuit of kisspeptin antagonists, Roseweir et al.(2009) designed 
and tested several KP10 analogs. Of the analogs tested, peptide 234 was 
identified as the most potent antagonist for the GPR54 receptor (Roseweir et al., 
2009). However, during the development of this antagonist, several other 
kisspeptin analogs were produced. In the present study, a selection of these 
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analogs that had antagonistic potential (unpublished) (Table 12) were chosen and 
their ability to bind and activate the GPR147 receptor was investigated. 
Table 12: Amino acid sequence of KP10 analogs 
Peptide 0 1 2 3 4 5 6 7 8 9 10  
KP10  Y N W N S F G L R F NH2 
234 Ac D-A N W N G F G D-W R F NH2 
349 D-A Y N W D-A Sar F Sar D-W R F NH2 
356 D-A Y N W N G F G D-W K F NH2 
351 D-A Y N A N Sar F Sar D-W R F NH2 
352 D-A Y N W N G F G D-W R F NH2 
353 D-A Y N W N Sar F Sar D-W R F NH2 
                        Ac = acetylated, Sar = sarcosine 
5.2.1 Binding affinity of kisspeptin analogs at GPR147  
The binding affinity of the peptide 234 antagonist and other KP10 analogs were 
assessed using whole-cell radioligand competition binding assays. Briefly, 
GPR147 transfected COS-7 cells were incubated with [125I]-RFRP3 in the 
absence or presence of increasing concentration of unlabelled test peptide. 
RFRP3 served as the control and was able to maximally displace [125I]-RFRP3 
with an IC50 of 4 nM (Figure 25, Table 13). The receptor expression B0, was 
similar in all cases and served as a baseline from which displacement could be 
compared for the different analogs (Figure 25). In agreement with the data 
presented in Chapter 4, KP10 was able to fully displace [125I]-RFRP3 binding, 
albeit with lower affinity than RFRP3. However, the potent kisspeptin antagonist, 
peptide 234, was not able to displace [125I]-RFRP3 indicating low/no affinity of this 
peptide for GPR147 (Figure 25a, Table 13). Peptide 356 also had very low affinity 
for GPR147 (700-fold less than RFRP3). However, it was found that peptide 349 
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had only 8-fold lower affinity for the GPR147 receptor than RFRP3 and a similar 
affinity to KP10. 
 
Additional analogs based on peptide 349 were subsequently tested (Figure 25b, 
Table 13). These peptides all had the addition of a D-Ala in position 0 and a D-
Trp substitution at position 8 of KP10. These analogs all displayed affinity for 
GPR147 and were able to displace [125I]-RFRP3 (Figure 25b, Table 13). Peptide 
351 had 30-fold lower affinity for GPR147 than RFRP3 and was the only analog 
to have a lower affinity than KP10 (16-fold). Peptides 352 and 353 both had a 
higher affinity (approx. 5-fold) for GPR147 than KP10 and had only slightly 












































































Figure 25: Radioligand competition binding assay with WT-GPR147 and kisspeptin analogs. COS-7 
cells were transfected with WT-GPR147. 48 hours later whole cell radioligand competition binding was 
performed. 100,000cpm/well [125I]-RFRP3 was incubated with cells in the absence (0) and presence of 
increasing concentrations of unlabelled peptide for 4 hours at 4 C, before washing and measurement of 
bound radioligand. (a) Binding affinity of select KP10 analogs. (b) Binding affinity of select KP10 analogs 
based on pep 349 substitutions. n=3. 
 
Table 13: IC50 and B0 values of kisspeptin analogs. (* p<0.05 for comparison with RFRP3, N=3) 
Peptide IC50 ± SEM (nM) 
RFRP3 4.06 ± 1.44 
KP10 53.72 ± 12.69* 
234 ND 
349 46.47 ± 18.97* 
356 4103 ± 4102* 
351 93.76 ± 11.04* 
352 13.31 ± 3.86 
353 6.96 ± 0.90 
                                                                    ND= no displacement  
5.2.2 Activation of GPR147 by kisspeptin analogs  
The kisspeptin analogs were then subjected to CRE-luciferase assays in order to 
measure their ability to simulate activation of GPR147. Briefly, GPR147 
transfected HEK293-T cells were stimulated with 1µM FSK and increasing 
concentration of peptide for five hours. Thereafter, CRE-luciferase luminescence 
was measured and was normalised against Renilla-luciferase signal. 
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RFRP3 served as the positive control and it was able to significantly reduce FSK-
induced cAMP production (Figure 26, Table 14). KP10 was also able to inhibit 
FSK-induced cAMP production to a similar level as RFRP3 (Figure 26a, Table 
14a) but with slightly reduced (2-fold) potency. Peptide 234 had no effect on 
receptor activation, which can be attributed to its low binding affinity. Peptide 356, 
which also had severely reduced binding affinity, was able to activate the 
receptor, albeit with 15-fold lower potency than RFRP3 but a similar maximal 
response/efficacy (Emax). Peptide 349 was 10-fold less potent than RFRP3 and 
although the maximal effect seen with this peptide was lower than for RFRP3, 
this difference was not significant (p>0.05).  
Of the peptides tested that were based on peptide 349 design, peptide 351 had 
6-fold reduction in potency and 2-fold reduction in Emax compared to RFRP3 
(Figure 26b,Table 14) and there was no significant difference in the potency or 
efficacy of peptides 352 and 353 for GRP147 compared to RFRP3 (p>0.05). 
In summary, some KP analogs are able to act as agonists of GPR147. The 
kisspeptin antagonist peptide 234 was found to have no affinity or activity at 
GPR147. This is important as peptide 234 therefore represents a selective 
GPR54-specific antagonist. Conversely, peptides 352 and 353 appear to be 































Figure 26: Forskolin inhibition assay of GPR147 with (a) kisspeptin analogs and (b) kisspeptin 
analogs based on peptide 349 substitutions. GRP147 transfected HEK293-T cells were incubated 1µM 
FSK with or without increasing peptide concentration for 5 hours. Cells were lysed then assayed for 
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Table 14: EC50 and Emax values for WT-GPR147 with kisspeptin/ kisspeptin analogs (* p<0.05 for 
comparison with WT-GPR54, N=3)  
 
Peptide EC50 ±SEM  EMax (RLU) ±SEM  
RFRP3 0.74 ± 0.65 6.76 ± 1.88 
KP10 0.47 ± 0.03 5.63 ± 0.25 
234 NI NI 
356 4.43 ± 0.85 6.36 ± 0.39 
349 2.63 ± 0.35 7.75  ± 0.27 
351 8.61 ± 0.96* 17.59 ± 1.40 
352 1.61 ± 1.24 12.40 ± 0.86 
353 1.51 ± 0.70 13.75 ± 0.50 
                                                    NI=no inhibition 
  




The aim of this study was to investigate the ability of kisspeptin analogs to bind 
and activate the GPR147 receptor. The endogenous kisspeptins have been 
shown to interact with GPR147 and GPR74 (Oishi et al., 2010,  Lyubimov et al., 
2010). The data presented here concurs with these finding as KP10 was found to 
have a high affinity and potency at GPR147. The kisspeptin antagonist, peptide 
234, however, had low affinity and was not able to activate the GPR147 receptor. 
The ability of  synthetic analogs to antagonize/activate only their target receptors 
(GPR54 in this case) is an important characteristic for the development of 
research tools or potential therapeutic agents.  
Roseweir et al. (2009) designed multiple kisspeptin analogs in an attempt to 
identify novel kisspeptin antagonists. In this study we performed binding and 
activity assays at GPR147 on previously untested kisspeptin analogs to 
determine if they had agonist/antagonist activity at this receptor. Kisspeptin 
analogs were selected on their antagonistic potential (Unpublished, Roseweir, 
2009). 
Peptide 356 has a lysine substituted for the arginine of the C-terminal of KP10. 
This modification resulted in a significant reduction in affinity (800-fold) for 
GPR147, possibly due to the disruption of the RF-NH2 functionality. This is 
comparable to data for which substitution of  the RF-NH2 arginine NPFF with a 
lysine residue induced a 720-fold decrease in affinity at the GPR74 receptor 
(Mazarguil et al., 2001). In general, the potency of the analogs tested reflected 
their binding affinity at the receptor. The exception was peptide 356 which 
although it had severely reduced binding affinity, had similar potency for 
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activation of GPR147 as the analogs with higher affinity. This suggests that this 
receptor, although impaired in its binding to the receptor, may be more effective 
at activating it once bound, and that the RF-amide functionality is not important 
for receptor activation. Peptide 351 had similar affinity as KP10 for GPR147 but 
almost 20-fold lower potency. This peptide differs from the other analogs as the 
tryptophan in position 3 of KP10 is replaced with an alanine. These data therefore 
indicate that this tryptophan of KP10 is important for GPR147 activation but not 
binding. 
Peptide 352 and 353 were both found to be potent GPR147 agonists with similar 
affinities/potencies, therefore suggesting that the sarcosine/glycine substitutions 
at positions 5 and 7 of KP10 have similar effects and do not affect 
binding/receptor activation and may actually serve to increase the affinity of these 
ligands. Both peptides 352 and 353 displayed high affinity and potency at 
GPR147. Indeed, the affinity of these analogs for GPR147 was 5-fold greater 
than that of KP10 or the related peptide, peptide 349. Analog, 349, displayed 
similar affinity but slightly lower potency than KP10 at GPR147. In contrast to 
peptide 349, the 352 and 353 analogs do not contain an amino acid substitution 
in position 4 of KP10. These data therefore suggest that asparagine in position 4 
of KP10 could be important for GPR147 receptor activation. 
In summary, this study has confirmed that KP10 has high affinity and potency at 
GPR147 and has identified several kisspeptin analogs that function as potent 
agonists at GPR147. The information gained is valuable for validating the 
receptor specificity of these compounds as a pre-requisite for the development of 
these analogs as research/therapeutic tools. In addition, the SAR information 
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obtained may aid in the development of other similar analogs and help to further 
our understanding of the ligand-receptor interactions of this important receptor.    
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Kisspeptin is a member of the RFamide neuropeptide family which has recently 
been discovered to play an important role in the hormonal control of reproduction, 
a finding that has been credited as one of the most important findings in the last 
decade in the field of reproductive biology. Studies have provided evidence that 
administering kisspeptin either centrally, via the ventricles of the brain, or 
peripherally via blood vessels, leads to a dose dependent increase in the 
gonadotropins LH and FSH. These studies have been conducted in numerous 
different species, including humans (Dhillo et al., 2005).  
As mentioned earlier, kisspeptin-GPR54 and RFRP3-GPR147 systems are 
known to regulate GnRH release in a positive and negative manner, respectively. 
RFRP3 acts in an opposite manner to kisspeptin to decrease plasma 
gonadotropin levels in mammals in vivo (Kriegsfeld et al., 2010,  Clarke et al., 
2012).  
As emphasised earlier, the promiscuity of certain RFamide peptides is high and 
this drives the need to develop receptor selective agonists and antagonists. We 
have shown that KP10/KP10 analogs are able to bind to and activate GPR147 
(Chapter 4 and 5). In this chapter reciprocal studies have been performed in 
which the binding affinity and potency of various RFamide, RFRP3 analogs and 
kisspeptin analogs at the GPR54 receptor have been studied.  
 
 




 To investigate the binding affinity and potency (as measured by inositol 
phosphate  stimulation) of selected RFamides, KP10 analogs and RFRP3 
analogs at the GPR54 receptor, in order to determine a ligand-selectivity 
profile for this receptor and to determine SAR data which may aid in the 
development of novel ligands targeting this important receptor. 
6.2 Results 
In Chapters 4 and 5 the ability of several RFamides, RFRP3 analogs and KP10 
analogs to bind to and activate the GPR147 receptor was examined. In this 
Chapter, the ability of the same ligands to interact with the GPR54 receptor has 
been investigated.  
6.2.1 Binding affinity and activation of GPR54 by selected RFamides 
The binding affinity of RFRP3, NPY and PPY (Table 8) at GPR54 was examined 
in radioligand competition binding assays. Briefly, GPR54 transfected COS-7 
cells were incubated with labelled [125I]-KP10 in the absence or presence of 
increasing concentration of unlabelled peptide and the level of bound radioligand 
measured.  
KP10 was able to fully displace [125I]-KP10 binding (as expected some degree of 
NSB of [125I]-KP10 was observed) with an IC50 of 2 nM (Figure 27). As 
expected, the level of [125I]-KP10 binding in the absence of competing ligand 
(BO) was similar for all ligands tested (Figure 27). None of the peptides tested, 
namely RFRP3, NPY and PPY, were able to displace [125I]-KP10, indicating that 
these peptides have very low/no affinity for the GPR54 receptor.  
































Figure 27: Radioligand competition binding assay with WT-GPR54 and select RFamides. COS-7 cells 
were transfected with FLAG-tagged WT-GPR54. 48 hours later whole cell radioligand competition binding 
was performed. 50,000cpm/well [125I]-KP10 was incubated with cells in the absence (0) and presence of 
increasing concentrations of unlabelled peptide for 4 hours at 4 C, before washing and measurement of 
bound radioligand. N=3 
 
KP10 was able to stimulate a robust IP response with an EC50 39nM (Figure 28). 
However, none of the RFamides tested (RFRP3, PPY and NPY) elicited an IP 
response, reflecting their lack of affinity for this receptor.  
In summary, only the KP10 peptide had high affinity and could activate the 
GPR54 receptor and the other RFamides tested had very low or no affinity and 
could not activate GPR54. 
 
 



































Figure 28: IP accumulation assay with WT-GPR54 and RFamides. COS-7 cells transfected with WT-
GPR54 were stimulated with increasing concentrations of peptide and assayed for total radioactive inositol 
phosphate accumulation. N=3  
 
6.2.2 Binding affinity and activation of GPR54 by kisspeptin analogs 
In Chapter 5 it was shown that several KP10 analogs were able to bind to and 
activate GPR147. In this Chapter, the affinity and activity of these KP10 analogs 
(Table 12) at GPR54 has been examined in order to determine if there is any 
cross reactivity between the two receptors. These KP10 analogs have not been 
tested previously at GPR54 and were designed in our laboratory as part of a 
series of peptides attempting to identify kisspeptin antagonists.  
 
The affinity of the peptides for GPR54 was determined using radioligand 
competition binding assays. Briefly, GPR54 transfected COS-7 cells were 
incubated with labelled [125I]-KP10 in the absence or presence of increasing 
concentration of unlabelled peptide and the level of bound radioligand measured. 
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 The positive control, KP10, was able to displace [125I]-KP10 (in agreement with 
data in Figure 27) with an IC50 of 2nM (Figure 29). However, all of the KP10 
analogs tested, showed very poor displacement with IC50 values >300nM-815nM 
indicating that all the KP10 analogs tested had lower affinity for the GPR54 
































Figure 29: Radioligand competition binding assay with WT-GPR54 and kisspeptin analogs. COS-7 
cells were transfected with FLAG-tagged WT-GPR54. 48 hours later whole cell radioligand competition 
binding was performed. 50,000cpm/well [125I]-KP10 was incubated with cells in the absence (0) and 
presence of increasing concentrations of unlabelled peptide for 4 hours at 4 C, before washing and 
measurement of bound radioligand. N=3 
 
KP10 served as the positive control and was able to elicit a robust IP response (in 
agreement with Figure 28) with an EC50 of 56nM (Figure 30). However, none of 
the KP10 analogs tested elicited an IP response, reflecting their inability to bind to 
this receptor. 
In summary, although KP10 has high affinity for GPR54, the KP10 analogs tested 
are unable to bind to/activate this receptor. 
 


























Figure 30: IP accumulation assay with WT-GPR54 and kisspeptin analogs. COS-7 cells transfected with 
WT-GPR54 were stimulated with increasing concentrations of KP10 and assayed for total radioactive inositol 
phosphate accumulation. N=3. 
 
6.2.3 Binding affinity and activation of GPR54 by RFRP3 analogs 
For completion, despite the observation that RFRP3 did not bind nor activate 
GPR54 (Figure 27 and Figure 28), RFRP3 analogs (Table 10) were tested for 
their ability to bind and activate the GPR54 receptor. As some KP10 analogs 
were found to be able to bind and activate the GPR147 receptor (Chapter 5), we 
were interested to determine if there was a reciprocal relationship between the 
ligands.  
Single dose binding assays were used to screen the analogs for binding affinity.  
Briefly, GPR54 transfected COS-7 cells were incubated with [125I]-KP10 in the 
absence or presence of a single high concentration (1µM) of unlabelled test 
peptide and the level of bound [125I]-KP10 measured.  
1µM KP10 was able to displace [125I]-KP10, 4-fold (Figure 31). However, no 
displacement was observed with any of the RFRP3 analogs tested, indicative of 
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low/no affinity of these peptides for GPR54. As no response was seen with the 
high concentrations (1µM) of peptides used in this preliminary experiment, it was 













































Figure 31: Radioligand competition binding assay with WT-GPR54 and select RFamides. COS-7 cells 
were transfected with FLAG-tagged WT-GPR54. 48 hours later whole cell radioligand competition binding 
was performed. 50,000cpm/well [125I]-KP10 was incubated with cells in the absence (0) and presence of 1µM 
of unlabelled peptide for 4 hours at 4 C, before washing and measurement of bound radioligand. N=3 
. 
To confirm that none of the RFRP3 analogs could activate GPR54, single dose IP 
assays were performed. Briefly, COS-7 cells transfected with WT-GPR54, and 
loaded with [3H]-myo inositol, were stimulated with a single high concentration 
(1µM) of peptide. Thereafter total inositol phosphates were extracted, purified and 
radioactivity was counted. 
KP10 elicited robust IP production with a 40-fold increase compared to basal 
levels measured in the absence of peptide (Figure 32). However, none of the 
RFRP3 analogs tested stimulated IP production above basal levels, confirming 
that these ligands cannot activate the GPR54 receptor. 
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Figure 32: IP accumulation assay with WT-GPR54 and RFRP3 analogs. COS-7 cells transfected with 
WT-GPR54 were stimulated with increasing concentrations of peptide and assayed for total radioactive 
inositol phosphate accumulation. N=3. 
  




The aim of the studies described in this Chapter was to examine the ligand-
specificity of GPR54.  
In contrast to GPR147, which was able to bind/be activated by KP10/KP10 
analogues in addition to its cognate ligands, none of the RFamides examined, 
namely NPY, RFRP3, CCK and PPY, had measureable affinity or potency at 
GPR54 (Figure 27, Figure 28). Other NPFF ligands have been previously 
examined for their activity at GPR54, including NPSF and NPFF, and were also 
not recognized by this receptor (Lyubimov et al., 2010).  The galanin receptor, 
GAL1, has 45% homology to GPR54 but its cognate ligand, galanin, is also 
unable to bind GPR54 (Lee et al., 1999). 
Several of the KP10 analogs tested at GPR147 proved to be potent agonists for 
this receptor (Chapter 5). The activity of these analogs at the GPR54 receptor 
was therefore examined for comparison. The KP10 analogs tested had low 
affinity for GPR54 with affinities greater than 150-fold lower than KP10 (Figure 
29) and thus no activity at this receptor (Figure 30). The combination of amino 
acid substitutions therefore appears to significantly disrupt binding to GRP54.  
Several studies have attempted to identify the residues required to activate 
GPR54. Alanine and D-amino acid scans revealed that the five C-terminal amino 
acids of KP10 (phenylalanine6-phenylalanine10) are important for agonist activity 
(Niida et al., 2006). Analysis of KP13 identified the pharmacophore site of the 
kisspeptins as Phe9, arginine12, and phenylalanine13 (Orsini et al., 2007), with the 
peptide forming a helicoid conformation from asparagine7 to phenylalanine13, 
which corresponds to phenylalanine6-phenylalanine10 of KP10. The RF moiety, of 
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the RFamide ligands is evolutionarily conserved, indicating it has an essential 
role in receptor binding, supported by the impaired binding of the KP10 analog 
peptide 356 (which has a lysine9 modification, disrupting the RFamide moiety) to 
GPR54 and GPR147 in the present study.   
Roseweir et al, 2009 identified that the five N-terminal amino acids of KP10 are 
required for receptor activation with serine5 and leucine8 critical for agonist 
activity (Roseweir et al., 2009). These authors also identified the potent 
kisspeptin antagonist, peptide 234 (ac [(D)-A] NWNGFG [(D)-W] RFNH2) that 
contained seven residues conserved from KP10 and has high affinity for GPR54 
(Roseweir et al., 2009). The KP10 analogs examined in the present study 
(peptides 349 and 351-353) and which were found to have poor affinity for 
GPR54 also contain the D-tryptophan8 substitution of peptide 234, indicating that 
this substitution does not disrupt binding affinity. The low binding affinity of these 
peptides at GPR54 could thus be attributed to their additional substitutions which 
may disrupt the binding pharmacophore of KP10. In addition to their other 
modifications, all of these analogs contain a modified N-terminus  when 
compared to peptide 234, with a D-alanine substitution at position 0 of KP10 and 
no substitution at position 1 of KP10. The only different between peptide 352 and 
peptide 243 is this modified N-terminus, indicating that this modification is 
responsible for the loss of GPR54 binding affinity of this group of peptides, and 
highlighting the importance of the N terminal region of the peptide in receptor 
interaction.    
The activity of RFRP3 analogs at GPR54 was also examined. However, like 
RFRP3, the RFRP3 analogs were unable to bind/activate GPR54 (Figure 31, 
Figure 32). RFRP3 and KP10 share the RFamide moiety and residues with 
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similar amino acids properties namely serine and phenylalanine (position 3 and 4 
of KP10) and asparagine and leucine (position 3 and 4 of RFRP3). It is possible 
that the binding site of GPR147 is not as stringent as that of GPR54 which is why 
KP10 is able to bind GPR147 but RFRP3 cannot bind GPR54. Certainly, it 
appears that different ligand-receptor inactions are involved in the binding of 
ligand to these two receptors.  
Taken together, these results suggest that the molecular recognition by GPR54 
seems to be highly stringent and kisspeptin–selective unlike GPR147 which can 
be activated by RFamides. These data serve to highlight the importance of 
testing any new analogs for RFamide receptors against other RFamide receptor 
species before development as research/therapeutic agents.   
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This study has highlighted the importance of the ECL domains of GPR54 in 
receptor activation by kisspeptin, with the ECL2 domain playing the most critical 
role. The acidic residues on the ECL2 domain of GPR54 (E193 and E201) are of 
particular importance for receptor activation (Chapter 3) and it is postulated that 
these acidic residues may be involved in interaction with the basic arginine at the 
C-terminus of kisspeptin. Modification of the ECL domains also caused a 
reduction in cell surface expression of GPR54, most likely through a disruption of 
the correct folding of the receptor protein causing it to be retained in the 
endoplasmic reticulum by the cellular quality control machinery. As some degree 
of cell surface expression was measured, the degree of misfolding is not likely to 
be too severe.   
This study has also demonstrated that an acetylated six-amino acid peptide (pep 
251) was the minimum sequence required to bind and activate GPR147 (Chapter 
4) and thus contains the critical pharmacophore for this ligand. The SAR studies 
performed on hRFRP3 revealed that the glutamine in position 6 was important for 
GPR147 affinity but not for activation of this receptor. Four RFRP3 analogs were 
also identified as potent GPR147 agonists, namely peptide 251, 253 (Asn6-
RFRP3), 255 (Ala3-RFRP3) and 257 (Ala3, 6-RFRP3).  
In addition to RFRP3 and its analogs, KP10 and several KP10 analogs (peptides 
349, 351 and 352) were also identified as potent agonists at GPR147 (Chapter 
5), indicating some promiscuity of this receptor. This cross-talk between different 
ligands can add complications when designing ligands/drugs for research or 
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therapeutic use and could lead to unexpected off-target side-effects and these 
data serve to highlight the importance of determining receptor selectivity profiles 
when developing novel analogs for RFamide receptors.  
In some circumstances, ligand cross reactivity can be an advantage when the 
actions of ligand at two different receptors have an additive effect or can mediate 
each other. This study and others have demonstrated that KP10, an agonist at 
GPR54, also acts as an agonist at GPR147. This is interesting as these two 
receptors have opposing actions in the control of the HPG axis, but may reflect 
the evolution of an important control mechanism for this system to ensure that 
hormone secretion can be finely balanced.   
Unlike GPR147, the ligand specificity of GPR54 was shown to be highly stringent, 
and only KP10 was also able to bind/activate this receptor (Chapter 6). SAR 
study of the differences between the structure of KP10, the antagonist peptide 
234 and the KP10 analogs that displayed agonist activity at GPR147, has further 
highlighted residues important for interaction with/activation of GPR54 and/or 
GPR147. This information will be extremely valuable for the future development 
of analogs targeting these receptors.    
In summary, the data presented in this thesis provide a valuable insight into the 
ligand-receptor interactions involved in the GRP54/kisspeptin and GPR147/RFRP 
systems which not only serves to increase our understanding of how these 
important systems function and inter-pay in the control of reproduction, but also 
has provided information valuable for the design of novel compounds targeting 
one or both of these systems.  
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The chimeric GPR54 constructs were a gift from Professor Chris Hague of the 
University of Washington.  The chimeras were constructed using hGPR54 in pEYFP 
vector that had a C-terminal YFP tag. For the N-terminus chimera (Nterm) base pairs 
1-29  were removed from hGPR54 and replaced with the base pairs 1-72 (aa M1-
E24)  from human galanin receptor 2 (hGalR2). For the ECL1 construct base pairs 
309-357 were removed and replaced with base pairs 254-297 (aa 
IYTLDGWVGFCLLCK). ECL2, base pairs 540-600 were removed and replaced with 
base pairs 490-556 (aa RQSQLANLTVCHPAWSPRRR). Finally for the ECL3, base 
pairs 852-897 were removed and replaced with base pairs 783-816 (aa 
GQFPLTRATYA). A diagnostic digest using KPNI and BamHI was used for to verify 
the insertion of the constructs. 
 
  
Appendix I: GPR54-GalR2 Chimeras 













Individual GPR147 exons were amplified using mouse genomic DNA, Herculase 
II high fidelity DNA polymerase, which does not add a 3’ overhang to amplified 
DNA (Stratagene, UK) and modified exon-specific primers (boundaries are 
denoted by / ). Amplified exon DNA was purified by agarose gel electrophoresis, 
excision, centrifugal elution (Millipore, USA) and ethanol precipitation. Coding 
exons one and two were joined together in a second PCR reaction using exon 1F 
and exon 2R primers. The product of this reaction was mixed with amplified exon 
3 DNA and joined together in a PCR reaction using exon 1F and exon 3R 
primers.  The full length open reading frame cDNA fragment was purified 
following agarose gel electrophoresis as described above and digested with Hind 
III and Bam HI (Promega, UK). The digested DNA was purified by 
phenol/chloroform extraction and precipitated with a mixture of ammonium 
The GPR147 construct was made by Dr Kevin Morgan, HRSU, MRC, Edinburgh. 
PCR primers for mouse GPR147 were: 
Exon 1 F    5’ ggtaccaagctt / atggaggcggaaccctcccagcctc 3’ 
Exon 1 R    5’ cggtgataaggttgtccacgagggttgtgggca 3’ 
Exon1 -Exon 2 F    5’ acaaccttatcaccg / gttggccttttgacaatgccaca 3’ 
Exon2 R   5’ ctctccacggcaatggccaccagt 3’ 
Exon 2- Exon 3   F    5’ cattgccgtggagag / gttccgctgcatcgtacaccct 3’ 
Exon3 R    5’ ctcgagggatcc / tcaaatgttccaggctgggatagt 3’ 
 
Appendix II: Cloning GPR147 cDNA 
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acetate/ethanol/glycogen (Roche, UK). A proportion of the purified DNA was 
ligated into Hind III- Bam H I digested pcDNA3.1 using T4 DNA ligase and used 
to transform competent E.coli Top10 (Invitrogen, UK). Cloned plasmid DNA 
containing insert was subjected to automated DNA sequencing in both directions 
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